Analysis of PAX2 gene alterations in renal cell tumors by Patrício, Patrícia Carvalho
 
UNIVERSIDADE NOVA DE LISBOA 
 
FACULDADE DE CIÊNCIAS E TECNOLOGIA 
 
 
 
 
 
 
 
 
Patrícia Carvalho Patrício 
 
 
 
 
 
 
 
Analysis of PAX2 Gene Alterations  
in Renal Cell Tumors 
 
 
 
 
 
 
 
 
 
 
 
Porto 
2010 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UNIVERSIDADE NOVA DE LISBOA 
 
FACULDADE DE CIÊNCIAS E TECNOLOGIA 
 
 
 
 
 
Patrícia Carvalho Patrício 
 
 
 
 
Analysis of PAX2 Gene Alterations  
in Renal Cell Tumors 
 
 
Dissertation for applying to a Master’s Degree in Molecular 
Genetics and Biomedicine submitted to the Sciences and 
Technology Faculty of New University of Lisbon. 
 
 
 
Supervisor:  
Carmen de Lurdes Fonseca Jerónimo, PhD 
(ICBAS – U.Porto, IPO – Porto) 
 
Co-Supervisor: 
Rui Manuel Ferreira Henrique, MD, PhD 
(ICBAS – U.Porto; IPO – Porto) 
 
 
 
 
Porto 
2010 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The research project of this master thesis dissertation was developed at the Cancer Epigenetics 
Group, Department of Genetics and Research Center of the  
Portuguese Oncology Institute – Porto. 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACKNOWLEDGEMENTS 
i 
ACKNOWLEDGEMENTS 
 
First of all I wish to thank my supervisor, Prof. Carmen Jerónimo, for giving me the 
opportunity to work at the Cancer Epigenetics Group, for her guidance, and for all the 
support and encouragement. Thank you for the valuable advice and for helping me getting 
started in this world of Science! 
I would like to express my gratitude to Prof. Rui Henrique, my co-supervisor, for all 
the support and pertinent suggestions, and whose great contribution was fundamental for 
achieving the goals that were proposed. 
I am also grateful to Prof. Manuel Teixeira, the Director of the Department of 
Genetics and Research Center of the IPO Porto, for giving me the privilege to work at his 
lab. 
To Prof. José Paulo Sampaio, the coordinator of this Master Course, and Prof. Nuno 
Neves, my connection bond to the Faculdade de Ciências e Tecnologia of Universidade 
Nova de Lisboa, for their assistance and availability during the development and writing 
process of this thesis.  
A special thanks to the members of the Cancer Epigenetics Group, namely Vera, 
Mafalda, João, Inês and Malini, for your scientific training, helpful suggestions and 
personal support along this demanding, and sometimes arduous, journey. You undoubtedly 
gave me the most pleasant work atmosphere I could ever ask for! 
My thanks also to Maria, Isabel, Paula, Ricardo, Joana Santos and Joana Guedes for 
their friendship and support. This work year would not have been the same without our 
laughs and talks! 
Joana Vieira, Diogo and Susana Lisboa, I learned a lot from you and so I could not 
fail to thank you for your understanding, availability and pertinent suggestions in FISH. 
I also want to thank the Department of Anatomic Pathology for their essential 
contribution for this work, namely to Dr. Ângelo Rodrigues, to Paula Dias and to Isa 
Carneiro.  
I would like to thank the remaining members of the Genetics Department who 
provided me assistance during this year and whose good mood was always an important 
motivation in the lab. 
ACKNOWLEDGEMENTS 
 
ii 
Finally, I wish to sincerely thank my parents, my brother and my grandfather, 
Humberto, and my friends, whose unconditional support was essential at so many stages of 
my life including this one.  
 
 
This study was funded by grants from CI-IPOP-4 and the Calouste Gulbenkian 
Foundation (Project # 96474). 
ABBREVIATIONS 
iii 
 
ABBREVIATIONS 
 
AJCC American Joint Committee on Cancer  
BHD Birt-Hogg-Dubé  
BSA Bovine serum albumine 
ccRCC Clear cell renal cell carcinoma  
CD Collecting duct 
cDNA Complementary DNA  
chrRCC Chromophobe renal cell carcinoma  
CpG Cytosine-phosphate-Guanine 
DAPI 4’,6-diamidino-2-phenylindole 
DCT Distal convoluted tubule 
DEPC Diethyl pyrocarbonate  
DNA  Deoxyribonucleic acid 
DNMT DNA methyltransferase 
dNTPs deoxynucleotides triphosphates  
EDTA Ethylenediamine tetraacetic acid 
FFPE Formalin fixed paraffin embedded 
FH  Fumarate hydratase 
FISH Fluorescent in situ Hybridization 
FLCN Folliculin  
FRET Förster/ fluorescence resonance energy transfer 
GSTP1 Glutathione S-transferase pi 1 
HD Homeodomain  
HIF-α  Hypoxia-inducible factor alpha 
HPRT1  Hypoxanthine phosphoribosyltransferase 1 
IGF2  Insulin-like growth factor 2 
MBD Methyl-CpG-binding domain 
miRNA micro RNA 
mRNA  Messenger ribonucleic acid 
MSP Methylation-specific PCR 
NaSCN Sodium thiocyanate 
ABBREVIATIONS 
 
iv 
 
NL Nephron loop 
OP Octapeptide domain 
PAX2 Paired box 2 
PBS Phosphate buffer solution 
PCR Polymerase chain reaction 
PCT Proximal convoluted tubule 
PD Paired-box domain 
pRCC  Papillary renal cell carcinoma 
qRT-PCR Quantitative reverse transcription-polymerase chain reaction 
RCC  Renal cell carcinoma 
RCT Renal cell tumor 
RNA Ribonucleic acid 
SAH S-adenosylhomocystine 
SAM S-adenosylmethionine 
SDS Sodium dodecyl sulfate 
SPSS  Statistical Package for Social Sciences 
SSC Saline-sodium citrate 
TD Transactivation domain 
TNM  Tumor-nodes-metastases 
TSG  Tumor suppressor gene 
UB Ureteric bud 
VHL  Von Hippel-Lindau 
SUMMARY 
v 
 
SUMMARY 
 
Background: Renal cell tumors (RCT) represent a heterogeneous group of 
malignancies arising from the epithelium of the renal tubules. PAX2 (Paired-box 2) is a 
transcription factor belonging to the evolutionarily conserved paired-box family that is 
required during development of the central nervous system and genitourinary tract. PAX2, 
which is considered a proto-oncogene, is normally suppressed at the later stages of 
embryonic development and reactivated during the carcinogenic process in some cancer 
models. Previously published data indicate that significant expression of PAX2 protein 
occurs in three of the most prevalent renal cell tumor subtypes - clear cell RCC (ccRCC), 
papillary RCC (pRCC) and oncocytoma - but not in chromophobe RCC (chrRCC). 
Moreover, it has been reported that PAX2 expression could be repressed by aberrant 
methylation at the end of nephrogenesis. Finally, FISH and cytogenetic analysis, 
demonstrated loss of chromosome 10 (to which PAX2 is mapped) in 40 to 60% of chrRCC 
cases. 
Aims: The main goal of this study was to identify epigenetic and/or genetic 
alterations affecting the PAX2 gene in a series of renal cell tumors, representing the four 
major subtypes. Specifically, our aims were to: (1) analyze the expression of PAX2 in 
different renal cell tumor subtypes, both at mRNA and at protein level; (2) determine 
whether the regulation of PAX2 expression occurs by epigenetic mechanisms, by assessing 
its promoter methylation status; (3) analyze the association between PAX2 copy number 
and gene expression; (4) evaluate the potential use of PAX2 epigenetic/genetic alterations 
as a biomarker for discrimination between chrRCC and oncocytoma. 
Methodology: In this study, 120 samples of renal cell tumors (30 of each subtype: 
ccRCC, pRCC, chrRCC, and oncocytoma) and 4 normal kidney tissues were tested. First, 
PAX2 protein expression was assessed by immunohistochemistry and the PAX2 mRNA 
expression levels were determined by quantitative reverse transcription PCR (qRT-PCR), 
using HPRT1 as an endogenous control. The methylation status of PAX2 promoter was 
assessed by methylation-specific PCR using two different sets of primers that annealed to 
adjacent regions in the promoter. The relationship between the number of PAX2 copies and 
its expression in chrRCC was analyzed by FISH. 
The chi-square test or Fisher’s exact test were used to seek for differences in the 
frequency of immunoreactivity for PAX2 protein among the four RCT subtypes. 
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Differences in PAX2 mRNA expression levels among the four groups were assessed by the 
Kruskal-Wallis non-parametric test, followed by pairwise comparisons using the Mann-
Whitney U test, when appropriate. The relationship between FISH findings and 
immunoexpression results for chrRCC was assessed by a chi-square or Fisher’s exact test, 
and the directional measure Somers’d was also computed. Moreover, the association 
between FISH findings and PAX2 mRNA levels for chrRCC was estimated using the 
Kruskal-Wallis test. 
Results and Discussion: Immunohistochemical results showed high 
immunoexpression score (> 10% positive cells) for ccRCC (96.7%), oncocytoma (90%) 
and pRCC (56.6%), whereas chrRCC had low immunoexpression score (33.3%), and these 
differences reached statistical significance (p < 0.001). 
Concerning PAX2 mRNA expression, significant differences among the renal cell 
tumor subtypes (p < 0.001) were detected. Although PAX2 mRNA expression levels did 
not differ between ccRCC and pRCC, both were significantly higher when compared to 
chrRCC and oncocytoma (p < 0.001, except for papillary vs. oncocytoma: p = 0.011). 
Moreover, mRNA expression levels in renal oncocytomas also differed significantly from 
those of chrRCC (p < 0.001). Finally, transcript levels correlated with the 
immunoexpression results.  
No methylation was found in the renal cell tumor tissues or in the normal kidney 
tissues, using the two different sets of primers, excluding this epigenetic alteration as a 
putative mechanism for PAX2 downregulation in renal cell tumors. 
FISH analyses showed that 69% of chrRCC presented chromosome 10 monosomy, 
correlating with PAX2 immunoexpression and, thus, suggesting that this alteration might 
be responsible for low PAX2 expression. The remaining chrRCC cases had no 
chromosome 10/PAX2 copy number changes (23%) or displayed three to four copies (8%). 
However, no correlation was observed between chromosome 10/PAX2 copy number 
changes and mRNA expression levels, although, a positive trend was suggested. 
Conclusions: Although the PAX2 immunoexpression results in this study diverge 
slightly from those previously published, our findings confirm that it might be useful as an 
ancillary tool for the distinction between chrRCC and renal oncocytoma.  
This study was the first to determine PAX2 mRNA expression levels for the four 
most representative renal cell tumor subtypes, and these results were found to correlate 
with protein immunoexpression.  
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Importantly, we also demonstrated that PAX2 promoter methylation is not involved 
in PAX2 silencing in chrRCC. Indeed, FISH analysis showed that PAX2 downregulation in 
this tumor subtype is likely due to chromosome 10 monosomy. 
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RESUMO 
 
Introdução: Os tumores de células renais representam um grupo heterogéneo de 
tumores com origem no epitélio dos túbulos renais. O gene PAX2 (Paired-box 2) é um 
factor de transcrição da família Paired-box, conservada em termos evolutivos, sendo 
necessário durante o desenvolvimento do sistema nervoso central e genito-urinário. Este 
gene, considerado um proto-oncogene, é normalmente silenciado nos estadios finais do 
desenvolvimento embrionário e reactivado durante o processo carcinogénico em alguns 
modelos de cancro. Dados publicados anteriormente indicam que ocorre imuno-expressão 
significativa do PAX2 em três dos subtipos de tumores de células renais mais prevalentes – 
carcinoma de células renais de células claras (ccRCC), carcinoma de células renais papilar 
(pRCC) e oncocitoma – mas não no carcinoma de células renais cromófobo (chrRCC). Foi 
ainda descrito que a expressão do gene PAX2 poderia ser silenciada por metilação 
aberrante do promotor no final da nefrogénese. Finalmente, análises citogenéticas 
demonstraram que a perda do cromossoma 10 (no qual o PAX2 está localizado) ocorre em 
40 a 60% dos casos de chrRCC. 
Objectivos: O principal objectivo deste estudo foi identificar alterações genéticas 
e/ou epigenéticas do gene PAX2 numa série de tumores de células renais representativa dos 
quatro subtipos mais prevalentes. Especificamente, os nossos objectivos foram: (1) analisar 
a expressão do gene PAX2 em diferentes subtipos de tumores de células renais, tanto ao 
nível do transcrito (mRNA) como ao nível da proteína; (2) determinar se a regulação da 
expressão do gene PAX2 ocorre por mecanismos epigenéticos, analisando o estado de 
metilação do seu promotor; (3) analisar a relação entre o número de cópias do gene PAX2 e 
a sua expressão; (4) avaliar o potencial uso das alterações genéticas/epigenéticas do gene 
PAX2 como biomarcadores para a discriminação entre chrRCC e oncocitoma. 
Metodologia: Neste estudo foram testadas 120 amostras de tumores de células renais 
(30 amostras de cada subtipo: ccRCC, pRCC, chrRCC e oncocitoma) e 4 amostras de 
tecido de rim normal. Inicialmente, foi determinada a expressão da proteína por imuno-
histoquímica e os níveis de expressão do transcrito do gene PAX2 por PCR quantitativo de 
transcriptase reversa, usando o gene HPRT1 como controlo endógeno. O estado de 
metilação do promotor do gene PAX2 foi analisado através de PCR específico para 
metilação utilizando dois conjuntos diferentes de primers que hibridam em regiões 
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adjacentes no promotor. A relação entre o número de cópias do gene PAX2 e a sua 
expressão nos chrRCC foi analisada por hibridação fluorescente in situ (FISH).  
O teste de Qui-quadrado foi utilizado para pesquisar diferenças nas frequências de 
imunorreactividade para a proteína PAX2 entre os quatro subtipos de tumor de células 
renais. Para avaliar as diferenças nos níveis de expressão de transcrito entre os quatro 
grupos de tumores procedeu-se a um teste não-paramétrico de Kruskal-Wallis, seguido de 
comparações emparelhadas usando o teste U Mann-Whitney. A relação entre os resultados 
de FISH e de imunoexpressão foi determinada utilizando o teste de Qui-quadrado e o teste 
de Somers’d. Adicionalmente, a associação entre os resultados de FISH e os níveis de 
expressão de transcrito foi estimada utilizando um teste de Kruskal-Wallis. 
Resultados e discussão: Os resultados da análise imuno-histoquímica revelaram 
elevada frequência de imunorreactividade (mais de 10% de células positivas) em ccRCC 
(96,7%), oncocitoma (90%) e pRCC (56,6%), enquanto que o chrRCC apresentou uma 
baixa frequência de imunorreactividade (33,3%), sendo estas diferenças estatisticamente 
significativas (p < 0,001). 
Relativamente à expressão do transcrito do gene PAX2, foram detectadas diferenças 
significativas entre os diferentes subtipos de tumores de células renais (p < 0,001). Apesar 
de não terem sido detectadas diferenças nos níveis de transcrito entre ccRCC e pRCC, 
ambos apresentaram níveis significativamente mais elevados quando comparados com 
chrRCC e oncocitoma (p < 0,001 excepto no caso de pRCC vs. oncocitoma: p = 0,011). 
Além disso, os níveis de expressão de transcrito nos oncocitomas também diferiram dos 
encontrados para chrRCC (p < 0,001). Os níveis de transcrito correlacionaram-se 
significativamente com os resultados de imuno-histoquímica. 
Não foi identificada metilação do promotor do PAX2 tanto nos tumores de células 
renais como no tecido renal normal, usando ambos os conjuntos de primers. Assim, esta 
alteração epigenética ficou excluída como mecanismo responsável pela sub-expressão do 
gene PAX2 em tumores de células renais. 
A análise de FISH revelou que 69% dos casos de chrRCC apresentava monossomia 
do cromossoma 10, correlacionando-se com a imuno-expressão, sugerindo que esta 
alteração deverá ser responsável pela sub-expressão do gene PAX2. Os restantes casos de 
chrRCC não apresentaram alterações do número de cópias do cromossoma 10/gene PAX2 
(23%) ou apresentaram três ou quatro cópias (8%). Contudo, não foi verificada correlação 
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entre o número de cópias do cromossoma 10/gene PAX2 e os níveis de expressão de 
transcrito, apesar da aparente tendência de associação entre os dois parâmetros. 
Conclusões: Apesar de os resultados de imuno-histoquímica para o gene PAX2 neste 
estudo divergirem ligeiramente dos previamente publicados, eles confirmam que esta pode 
ser útil como ferramenta auxiliar para a distinção entre chrRCC e oncocitoma. 
Este estudo foi o primeiro a determinar os níveis de expressão de transcrito do gene 
PAX2 nos quatro subtipos de tumores de células renais mais representativos e estes 
resultados mostraram estar correlacionados com a imuno-expressão. 
Também demonstramos que a metilação do promotor do gene PAX2 não está 
envolvida no silenciamento deste gene nos chrRCC. De facto, a análise de FISH indica que 
a sub-expressão do gene PAX2 neste subtipo de tumor se deverá à monossomia do 
cromossoma 10. 
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INTRODUCTION 
 
1. Anatomy and Histology of the Kidney 
The urinary system consists of six organs: two kidneys, two ureters, the urinary 
bladder, and the urethra (Saladin, 2001). 
The most fundamental roles of the kidneys are homeostatic balance of the volume 
and composition of the body fluids, such as the blood plasma, tissue fluid, and intracellular 
fluid, the removal of waste products from the blood, and the regulation of the blood 
pressure by secreting several hormones (Chow et al., 2010). 
Each kidney is composed of a parenchyma and a collecting system. The parenchyma 
includes an outer cortex and an inner medulla, and is composed of about 1.2 million 
functional units, the nephrons. Each nephron consists of three principal parts: the blood 
vessels, the renal corpuscle, and a long renal tubule.  
The renal corpuscle consists of a glomerulus enclosed in a two-layered glomerular 
(Bowman’s) capsule. The fluid that filters from the glomerular capillaries is called the 
glomerular filtrate. 
The renal tubule is a duct that leads away from the glomerular capsule and is divided 
into four major regions: the proximal convoluted tubule (PCT), the nephron loop (loop of 
Henle, NL), the distal convoluted tubule (DCT), and the collecting duct (CD). Each region 
has specific physiological functions in the production of urine. The PCT arises from the 
glomerular capsule and is the longest of the four regions, dominating the histological 
sections of renal cortex, and is where most of the absorption occurs. The following region 
is the loop of Henle, a long U-shaped structure which is divided into the thick and the thin 
segments. The thick segment cells are engaged in the active transport of salts, and have a 
very high metabolic activity as it is reflected by its large amount of mitochondria. The thin 
segment cells have low metabolic activity but are very permeable to water (Saladin, 2001). 
The DCT is shorter and less convoluted than PCT, and so fewer sections are seen in 
histological sections. This region determines the end of the nephron.  
Finally, the collecting duct consists of the region to which several nephrons drain 
into (Saladin, 2001). 
The nephrons are supported by a mesenchyme composed by interstitial cells 
interspersed with extracellular matrix elements, nerves and vessels. Interstitial cells may be 
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divided in renal fibroblasts and cells of the immune system, and are engaged in the 
modeling of the extracellular matrix, in the production of regulatory substances, including 
erythropoietin, and in immune processes (Lemley and Kriz, 1991). 
 
 
 
2. Kidney Cancer 
2.1 Epidemiology 
Cancer is currently the second major cause of death in Western World countries, and 
kidney cancer accounts for approximately 4% of all cancers, being the 7th most common 
cancer in men and the 8th most common in women (Jemal et al., 2010). 
In 2008, approximately 167,947 new cases of kidney cancer were diagnosed and 
72,030 persons died because of this malignancy, worldwide (Ferlay et al., 2010b). 
In Europe, the estimated number of kidney cancer cases and deaths in 2008 was 
88,400 and 39,300, respectively, for both sexes. In Portugal, the estimated incidence of 
kidney cancer cases in 2008 was 4.3 and 2.5 hundreds, for males and females, respectively 
(Ferlay et al., 2010a). Mortality to incidence ratio in kidney cancer is higher compared to 
other urological malignancies (Lindblad, 2004). 
Adult kidney cancers arising in the renal parenchyma are mainly adenocarcinomas, 
also known as renal cell carcinomas (RCC). Those arising from the collecting system are 
mainly transitional cell carcinomas (Chow et al., 2010). Renal cell carcinomas represent 
more than 90% of all renal malignancies occurring in adults in both sexes being the 12th 
most common cancer in men and the 17th in women (Eble et al., 2004). 
The incidence of RCC varies considerably worldwide. The highest incidence rates 
are registered in Europe, North America and Australia, while the lowest occur in Asia, 
South America and Africa (Figure 1) (Ferlay et al., 2010b). 
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Figure 1: Worldwide distribution of kidney cancer incidence. In 2008, the highest incidence rates for this 
malignancy, for both genders, were registered in Europe, North America and Australia.   
Adapted from IARC, GLOBOCAN, 2008 (Ferlay et al., 2010b). 
 
The incidence rates for this carcinoma have been rising each year in some developed 
countries. This fact cannot be explained completely by the use of imaging techniques, 
which improves early detection of small size tumors, but also by the increasing etiologic 
risk factors prevalence and exposure (Lindblad, 2004). 
 
2.2 Risk factors  
Renal Cell Carcinoma etiology is difficult to address. However, some risk factors 
have been consistently reported to be positively associated with this malignancy. 
Gender, age, ethnicity, cigarette smoking, obesity, dialysis treatment, hypertension 
and use of antihypertensive medication are some of those risk factors already reported. 
 
2.2.1 Gender, Age and Ethnicity 
Renal cell carcinoma is more frequent in men than in women, with a men to women 
ratio of 3/2 (Lindblad, 2004). 
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Older individuals are at higher risk compared with young individuals. In fact, the 
peak incidence occurs in the sixth decade, with the majority of the cases (80%) occurring 
within 40 to 69-year-old population (Pascual and Borque, 2008). 
Kidney cancer incidence is 10 to 20% higher in african-americans although the 
reason is not completely understood (Chow et al., 1999).  
 
2.2.2 Cigarette smoking 
This is one of the most well established risk factors for RCC and is thougth to 
account for approximatly 39% of all cases in males. However, increased risk has most 
often been found in long-term or heavy smokers (Muscat, 2000). 
The two major classes of tobacco carcinogens are the polycyclic aromatic 
hydrocarbons (PAH) such as benzo[a]pyrene and the tobacco-specific nitrosamines. Most 
of these tobacco smoke constituents are metabolized or excreted. Although it is not clear 
which of these constituents are responsible for RCC, some studies reported that 
nitrosamines could induce renal tumors in several animal species (Muscat, 2000). 
 
2.2.3 Dialysis 
Approximately 45% percent of dialysis patients develop acquired cystic disease of 
the kidney. These patients show a 30 times higher risk for developing RCC than the rest of 
the general population (Pascual and Borque, 2008; Anglada Curado et al., 2009). 
 
2.2.4 Hypertension and antihypertensive medication 
Hypertension and the use of antihypertensive medication have been reported to be 
risk factors for RCC in several epidemiological studies. It is unclear, however, whether the 
increased risk is caused by hypertension itself, or by the use of antihypertensive 
medication. The mechanisms contributing to this increased risk are not totally understood 
but it seems that the consequent metabolic and/or functional changes in the renal tubular 
cells may underlie the onset of carcinogenesis (Pascual and Borque, 2008). 
 
2.2.5 Obesity 
Several epidemiological studies correlate hypercaloric diet and obesity with an 
increased risk for developing RCC. The mechanism by which obesity causes kidney cancer 
is not very clear, but it has been hypothesized that it may be due to secondary hormonal 
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changes, decreased immune system, or associated hypertension and/or diabetes mellitus 
(Pascual and Borque, 2008; Lowrance et al., 2010). Although this is a very discussed 
putative risk factor, direct evidence for these mechanisms in humans is limited. 
 
2.2.6 Inheritance 
Although most of the cases of RCC are sporadic, approximately 4% of the Renal Cell 
Carcinomas are associated with hereditary syndromes. The presence of multiple neoplastic 
renal lesions or family history suggest genetic predisposition to this disease (Anglada 
Curado et al., 2009). 
There are four major hereditary syndromes that predispose to RCC: The Von Hippel-
Lindau syndrome, hereditary leiomyomatosis and renal cell carcinoma, Birt-Hogg-Dubé 
syndrome and hereditary papillary RCC. 
 
Von Hippel-Lindau (VHL) syndrome: 
This syndrome is caused by germline mutations of the VHL tumor suppressor gene, 
located on chromosome 3p25-26. Heritable clear cell RCC is caused by a germline 
mutation of one allele and an acquired mutation of the second allele. These germline 
mutations are identified in nearly 100% of VHL-families (Baldewijns et al., 2008). The 
VHL protein has an important role in cell cycle regulation and angiogenesis (Maxwell et 
al., 1999).  
Clinical manifestations include, among others, the risk for development of RCC, 
pheochromocytoma, pancreatic cysts and retinal angiomas. The RCC is of the clear cell 
type and may be solid or cystic (Rosner et al., 2009). Fourty to sixty percent of the patients 
with this syndrome present a RCC (Pascual and Borque, 2008). 
 
Hereditary papillary renal cell carcinoma: 
This is an inherited tumor syndrome with autosomal dominant trait and of late onset, 
with multiple bilateral papillary RCCs type I. The disease is caused by activating mutations 
of the MET proto-oncogene which maps the chromosome 7q31.1 (Pascual and Borque, 
2008). Trisomy of chromosomes 7 and 17 are typical of these tumors, which is also 
common in the sporadic papillary RCC (Lopez-Beltran et al., 2009). 
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Hereditary leiomyomatosis and renal cell carcinoma: 
This is an autosomal dominant tumor syndrome characterized by germline mutations 
in the fumarate hydratase (FH) gene, located in the chromosome 1q42.3–q43. Mutations in 
this gene can produce an overexpression of hypoxia inducible factors HIF-1α and HIF-2α 
leading to the activation of several hypoxia-inducible gene targets (Algaba, 2010). Patients 
who have this syndrome have the tendency to acquire cutaneous and uterine leiomyomas, 
and occasionally papillary renal cell carcinoma type II and uterine leiomyosarcomas 
(Pascual and Borque, 2008). Loss of heterozygosity at 1q32 and 1q42-44 is frequently 
found. These tumors usually have poor prognosis and frequently spread to regional lymph 
nodes (Lopez-Beltran et al., 2009). 
 
Birt-Hogg-Dubé syndrome: 
This is a hereditary cancer syndrome with an autosomal dominant inheritance pattern 
as well. It is characterized by benign skin tumors and multiple renal tumors, such as 
chromophobe RCC (33%), hybrid tumors (50%) and oncocytoma (35%). Clear cell RCC 
has also been identified in several cases (Pascual and Borque, 2008; Rosner et al., 2009).  
The gene associated with this syndrome, known as FLCN or BHD that maps to the 
chromosome 17p11.2, encodes a protein called folliculin which is truncated as a result of 
insertions, deletions, or nonsense mutations. This is a characteristic tumor suppressor gene 
and is also involved in sporadic RCC (Pascual and Borque, 2008; Rosner et al., 2009). 
 
 
3. Pathology and Classification 
 
Renal cell tumors (RCT) represent a heterogeneous group of neoplasms arising from 
the epithelium of the renal tubules. Histological and molecular evaluation of this group of 
tumors has resulted in the development of a universal classification consisting of several 
different RCT subtypes (Baldewijns et al., 2008). The Heidelberg classification of RCT 
emerged in 1996, and integrates data from recognizable histological criteria and genetic 
changes (Kovacs et al., 1997). A diagram representing this classification system is shown 
in Figure 2.  
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Figure 2: Diagram representing the different subtypes of RCC according to the “Heidelberg” 
classification. Localization of the subtypes and cytogenetic changes associated to each subtype.  
Adapted from (Bodmer et al., 2002). 
 
This classification separates benign from malignant epithelial neoplasms. It 
comprises three major histological subtypes of renal cell carcinoma (RCC): clear cell RCC, 
papillary RCC and chromophobe RCC. Collecting duct RCC is a fourth, less common, 
subtype of malignant renal tumor. Other rare variants are also recognized. Benign tumors 
have been subclassified into metanephric adenoma/adenofibroma, papillary renal cell 
adenoma and renal oncocytoma, the most common of these (Bodmer et al., 2002). 
 
3.1 Clear cell Renal Cell Carcinoma 
Clear cell RCC (ccRCC) or common RCC is the most frequent subtype of RCC. It 
comprises more than 70% of all RCCs and is thought to arise from the proximal 
convoluted renal tubule (Kovacs et al., 1997). This is a malignant neoplasm composed of 
cells with clear or eosinophilic cytoplasm within a fragile vascular network (Figure 3, A) 
(Eble et al., 2004). 
Loss of sequences at chromosome 3p is a characteristic somatic genetic feature in the 
vast majority of sporadic clear cell RCC (Teyssier et al., 1986). This finding suggests the 
presence of one or more TSG relevant for RCC development on this chromosomal arm. 
The VHL tumor suppressor gene is one of the genes located at 3p and biallelic VHL 
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inactivation is seen in a high proportion of RCCs. This inactivation follows the Knudson’s 
two-hit model, and may occur through mutation (34-56% of the cases), deletion or 
promoter methylation (19% of the cases) (Bodmer et al., 2002). 
The VHL protein acts by down-regulating the hypoxia-inducible factor, which is 
responsible for the activation of genes involved in several cellular processes, such as 
proliferation, neo-vascularization, and extracellular matrix formation (Eble et al., 2004). 
 
3.2 Papillary Renal Cell Carcinoma 
Papillary RCC (pRCC) is encountered in 10 to 15% of nephrectomy series (Fleming, 
2000), thus being the second most common carcinoma of the kidney. It is a malignant 
parenchymal neoplasm with papillary or tubulopapillary architecture (Figure 3, B and C) 
(Eble et al., 2004) and has a less aggressive clinical course compared to clear cell RCC 
(Lopez-Beltran et al., 2009). 
pRCC is classified in two different subtypes, type I (Figure 3, B) and type II (Figure 
3, C), depending on the morphology of the tumor cells covering the papillary lesions. This 
renal cell tumor, like ccRCC, arises from cells in the proximal convoluted renal tubule 
(Kovacs et al., 1997). The commonest karyotypic alterations associated with this 
carcinoma are trisomies of chromosomes 7 and 17, and Y chromosome loss. Trisomy of 
chromosomes 12, 16 and 20 are also found and may be related to tumor progression (Eble 
et al., 2004). pRCC also exhibits somatic mutations of the MET proto-oncogene, which 
encodes a tyrosine kinase growth factor receptor for hepatocyte growth factor located on 
chromosome 7 (Schmidt et al., 1997).  
 
3.3 Chromophobe Renal Cell Carcinoma 
The third most common RCC subtype is chromophobe RCC (chrRCC), which is a 
less aggressive type of RCC (Lopez-Beltran et al., 2009), accounting for 5% of all renal 
neoplasms. It is thought to arise from the renal collecting duct cells (Bodmer et al., 2002), 
and is usually characterized by large pale cells with prominent cell membranes (Figure 3, 
D and E) (Eble et al., 2004).  
This tumor type is genetically characterized by massive chromosomal loss, most 
frequently of chromosomes 1, 2, 6, 10, 13, 17 and 21 (Eble et al., 2004). 
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3.4 Oncocytoma 
Oncocytoma is a benign renal epithelial tumor with large cells containing 
mitochondria-rich eosinophilic cytoplasm, thought to arise from intercalated duct cells 
(Figure 3, F). It comprises of about 5% of all renal tumors arising from tubular epithelium 
(Eble et al., 2004). 
In terms of somatic genetics, they usually display a mixed population of cells with 
normal and abnormal karyotypes. Some cases show the translocation t(5;11)(q35,q13) 
while others show loss of chromosomes 1 and 14 (Eble et al., 2004). Alterations in 
mitochondrial DNA is also a frequent feature of these tumors (Lopez-Beltran et al., 2009). 
 
3.5 Distinction among renal tumor subtypes 
Chromophobe RCC was first described in 1985 by Thoenes et al. and consists of two 
main variants, classical and eosinophilic, that can ultimately present overlapping features 
with both clearly malignant and benign renal tumors. The classical variant (Figure 3, D) is 
characterized by large polygonal cells with transparent, slightly reticulated cytoplasm and 
can be hard to distinguish from clear cell RCC. The eosinophilic variant (Figure 3, E), 
composed of intensely eosinophilic cells resembles oncocytoma (Thoenes et al., 1988).  
Since chromophobe RCC is a distinct type of renal cell carcinoma with an overall 
prognosis and biological behavior significantly better than those of clear cell RCC, 
although worse than those of oncocytoma, it is clinically important to make an appropriate 
distinction between these specific subtypes of renal neoplasms. 
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Figure 3: Main histologic types of renal cell tumors. (A) Clear cell Renal Cell Carcinoma; (B) 
Papillary Renal Cell Carcinoma, type I; (C) Papillary Renal Cell Carcinoma, type II; (D) Chromophobe 
Renal Cell Carcinoma, classical variant; (E) Chromophobe Renal Cell Carcinoma, eosinophilic variant; 
(F) Oncocytoma. Adapted from (Lopez-Beltran et al., 2009). 
 
 
 
 
3.6 Clinical and Pathological staging 
One of the most frequently used staging systems is the American Joint Committee on 
Cancer (AJCC) tumor-node-metastases (TNM) staging system. This classification system 
provides a defined description of the tumor, area and extent of invasion, and degree of 
vascular involvement. These criteria for tumor staging results in the grouping of RCC 
cases into four different stages (Nguyen and Campbell, 2006). 
Table 1 shows detailed information on TNM staging for kidney cancer. 
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Table 1: TNM staging and stage gouping for kidney cancer. 
T – Primary tumor 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
T1 Tumor 7 cm or less in greatest dimension, limited to the kidney 
T1a Tumor 4 cm or less in greatest dimension, limited to the kidney 
T1b Tumor more than 4 cm but not more than 7cm in greatest dimension, limited to the kidney 
T2 Tumor more than 7 cm in greatest dimension, limited to the kidney 
T2a Tumor more than 7 cm but less than or equal to 10 cm in greatest dimension, limited to the kidney 
T2b Tumor more than 10 cm, limited to the kidney 
T3 
Tumor extends into major veins or perinephric tissues but not into the ipsilateral adrenal gland 
and not beyond Gerota’s fascia 
T3a 
Tumor grossly extends into the renal vein or its segmental (muscle containing) branches, or tumor 
invades perirenal and/or renal sinus fat but not beyond Gerota’s fascia 
T3b Tumor grossly extends into vena cava below the diaphragm 
T3c Tumor grossly extends into vena cava above the diaphragm or invades the wall of the vena cava 
T4 
Tumor invades beyond Gerota’s fascia (including contiguous extension into the ipsilateral adrenal 
gland) 
N – Regional Lymph Nodes 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
M – Distant metastasis 
M0 No distant metastasis 
M1 Distant metastasis 
Stage grouping 
Stage I T1 N0 M0 
Stage II T2 N0 M0 
Stage III T1 or T2  N1  M0 / T3  N0 or N1  M0 
Stage IV T4  Any N  M0 / Any T  Any N  M1 
Adapted from AJCC Cancer Staging Manual, 2010 (Edge et al., 2010). 
 
INTRODUCTION 
 
12 
 
3.7 Histopathological grading 
Grading of RCC is based on the Fuhrman system, consisting of four grades. This 
grading system is based on the nuclear size, contour and conspicuousness of nucleoli 
(Fuhrman et al., 1982) and is the most important prognostic predictor in RCC, mainly for 
the clear cell type (Lopez-Beltran et al., 2009). 
 
3.8 Tumor prognosis 
There has been a gradual improvement in RCC prognosis over the last decades, with 
5-year relative survival rates as high as 64% in 2002, compared with less than 40% in the 
early 1960s (Baldewijns et al., 2008). 
Factors influencing prognosis can be classified into anatomical, histological, clinical, 
and molecular. Anatomical factors are usually included in the TNM staging classification 
system. The histological factors include the Fuhrman grade, RCC subtype, presence of 
sarcomatoid features, microvascular invasion, tumor necrosis and invasion of the collecting 
system. Clinical factors consist of patient performance status, localized symptoms, 
anaemia and platelet count. Finally, and concerning the molecular factors, numerous 
molecular markers have been investigated. However, to date, none of these markers has 
provided evidence to improve the predictive accuracy of existing prognostic systems 
(Ljungberg et al., 2010).  
In univariate analysis, there is a trend towards a better prognosis for patients with 
chrRCC when compared with pRCC and ccRCC. However, in multivariate analysis, TNM 
stage, Fuhrman grade and the performance status, but not histology, are preserved as 
independent prognostic variables. Tumor necrosis is also a strong independent predictor of 
poor outcome for ccRCC but not for chrRCC or pRCC. Microvascular invasion and 
presence of sarcomatoid features are also reported as adverse prognostic indicators 
(Baldewijns et al., 2008).  
The clinical behavior of RCC depends on complex interactions between several 
prognostic factors, however the currently available most useful predictors of patient 
outcome include patient performance status, tumor stage and grade (Baldewijns et al., 
2008). 
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4. Epigenetics 
 
The term “epigenetics” remounts to the fourth decade of the 20th century and was 
first referred as gene-environment interactions that ultimately lead to a particular 
phenotype. Waddington originally used this word in a developmental context to define the 
changes in gene activation and deactivation necessary for cellular differentiation (Franklin 
and Mansuy, 2009). Nowadays, the term refers to both mitotically and/or meiotically 
heritable changes in gene expression that are not accompanied by changes in the DNA 
sequence (Jones and Baylin, 2007).  
The epigenetic processes that stably alter gene expression patterns result from 
modifications of the DNA molecule or chromatin structure and include DNA methylation, 
post-translational histone modifications, and changes in microRNA patterns (Mulero-
Navarro, 2008). 
 
4.1 DNA Methylation 
DNA methylation is the most well studied epigenetic change. This modification 
occurs in almost all living organisms, from bacteria to plants and animals (Scarano et al., 
2005) and is suggested to lead to transcriptional silencing via several mechanisms (Gibney 
and Nolan, 2010). 
In the mammalian genome, methylation occurs essentially at cytosine bases that 
precede a guanosine, in the so-called CpG dinucleotides, where the ‘p’ represents the 
phosphodiester bond linking cytosine- and guanosine-containing nucleotides. These CpG 
dinucleotides are not randomly distributed in the genome, being preferentially located in 
short regions of 0.5 – 4 kb in length, known as CpG islands (Jones and Baylin, 2002). The 
majority of CpG islands can be found near the promoter regions of several genes and 
approximately 60% of human genes contain these CpG islands (Antequera and Bird, 
1993). 
DNA methylation is conducted by a family of DNA methyltransferase enzymes 
(DNMTs) that work through covalent addition of a methyl group to the fifth carbon 
position of cytosines (Lopez-Serra and Esteller, 2008) (Figure 4). Various DNMTs, with 
different specificities have been already described: DNMT1, the main enzyme that 
maintains DNA methylation during replication, showing preference for hemi-methylated 
DNA substrates; DNMT3a and DNMT3b which are involved in the generation of new 
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methylation patterns, targeting unmethylated CpG dinucleotides, and finally DNMT2 
whose biological function is not very well established (Mulero-Navarro, 2008). 
 
 
Figure 4: Formation of a 5-methylcytosine. A DNA methyltransferase enzyme catalyzes the transfer 
of a methyl group (CH3) from S-adenosylmethionine (SAM) to (deoxy)cytosine, producing 5-
(deoxy)methylcytosine and S-adenosylhomocystine (SAH). Adapted from (Attwood et al., 2002). 
 
In vertebrates, more than 80% of CpG dinucleotides that are not located in the CpG 
islands are frequently methylated. However, those within CpG islands are usually not 
methylated or show relatively low levels of methylation (Gibney and Nolan, 2010). 
In normal cells, DNA methylation is involved in processes such as gene dosage 
reduction in X-chromosome inactivation in females and genomic imprinting. Methylation 
also occurs at repetitive DNA sequences to promote chromosome stability (Lopez-Serra 
and Esteller, 2008).  
DNA methylation is accompanied by histone modifications that regulate chromatin 
structure and together they determine the transcriptional state of the DNA. Histones can be 
modified by acetylation, methylation, phosphorylation, glycosylation, sumoylation and 
ADP ribosylation, but the most frequent modifications are acetylation and methylation of 
lysine residues in the amino terminal of histone 3 and histone 4 (Bollati and Baccarelli, 
2010). Such modifications act sequentially or in combination to specify the “histone code”. 
The communication between DNA methylation and histone modifications probably occurs 
in both directions and might be partially mediated by nuclear factors with methyl DNA 
binding activity, such as the MBD (Methyl-CpG-binding domain) proteins. These proteins 
recognize single methylated CpG dinucleotides and are capable of recruiting histone 
modifying and chromatin remodeling complexes to the methylated sites (Figure 5) (Lopez-
Serra and Esteller, 2008). 
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Figure 5: Interplay between DNA methylation and histone modifications. MBPs bind to regions of 
methylated DNA and form complexes with histone deacetylases, HDACs. Similarly, proteins that either bind 
to modified histones (e.g., heterochromatin protein 1, HP1) or directly modify histones (e.g., lysine-specific 
demethylase 1, LSD1), recruit DNMTs to induce DNA methylation. DNMT: DNA methyltransferase, MBP: 
Methyl-CpG- binding protein, HDAC: Histone deacetylase, H: Histone, LSD1: Lysine-specific demethylase, 
HP1: heterochromatin protein 1. Adapted from (Handel et al., 2010). 
 
4.2 Methylation patterns in cancer 
In cancer cells, DNA methylation patterns are deeply altered (Figure 6). The cause of 
such alteration is not fully understood but could result from local alterations in DNMTs, 
which are expressed at higher levels in tumor cells (Jones and Baylin, 2002). 
The first epigenetic modification to be identified in cancer cells was an overall 
decrease of CpG methylation. The mechanisms that may explain the involvement of this 
global DNA hypomethylation with the onset and progression of cancer is the generation of 
chromosome instability, the reactivation of transposable elements and the loss of 
imprinting (Esteller, 2008). IGF2 (Insulin-like growth factor 2) and H19 are two well 
known examples of imprinted genes that become hypomethylated and are consequently 
overexpressed in cancer (Ehrlich, 2009). 
On the other hand, another frequent and early event in cancer is aberrant promoter 
methylation of tumor suppressor genes, which leads to their silencing and eventually to the 
development of the carcinogenic process. These genes are usually involved in cell cycle 
regulation, DNA repair, apoptosis, angiogenesis, invasion and adhesion (Lopez-Serra and 
Esteller, 2008).  
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Loss of GSTP1 expression, the gene encoding the drug detoxification enzyme 
gluthatione S-transferase π (GST- π), is frequently observed in prostate cancer and this 
gene silencing is directly associated with aberrant promoter methylation (Jeronimo et al., 
2001). This is an example of a gene that acts as a caretaker, protecting prostate cells 
against genomic damage mediated by a variety of oxidants. Thus, its loss predisposes 
normal prostatic cells to DNA damage leading to carcinogenesis (Costa et al., 2007a). 
Some CpG islands, associated with proto-oncogenes promoter regions, are 
methylated in non-neoplastic somatic cells. Therefore, in cancer cells, these promoter 
regions may become demethylated causing repressed oncogenes to be re-activated and/or 
overexpressed. HRAS (Harvey rat sarcoma viral oncogene homolog) and cMYC 
(Myelocytomatosis viral oncogene homolog) are some of the examples of this kind of gene 
re-activation associated to CpG islands loss of methylation. These activated oncogenes 
might be implicated in the onset of cellular transformation and/or tumor progression 
(Scarano et al., 2005) but evidence suggests a larger involvement in the activation of genes 
associated with tumor invasion and metastasis (Ehrlich, 2009). 
Aberrant promoter methylation patterns have also been reported to be involved in 
miRNA silencing. miRNAs are small non-coding RNAs that target specific genes and 
silence its protein expression. In cancer, the expression patterns of these miRNAs are 
profoundly altered (Lopez-Serra and Esteller, 2008). 
 
 
Figure 6: DNA methylation patterns in normal and in cancer cells. E, exon.  
Adapted from (Esteller, 2007). 
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4.3  Epigenetics in renal cell tumors 
Mutations and deletions do not cover 100% of the alterations found in sporadic and 
heritable RCC cases, and therefore aberrant gene promoter methylation (hyper- and hypo-) 
is thought to be an alternative event underlying at least some of the cases. In this respect, 
information concerning the gene methylation profile of renal cell carcinomas is relatively 
limited. 
Some candidate tumor suppressor genes (TSGs) silenced by hypermethylation have 
already been reported to be associated with RCC. A very good example of such a gene is 
the VHL tumor suppressor gene. Herman and colleagues first reported VHL promoter 
hypermethylation associated with gene silencing (Herman et al., 1994), as an alternative 
inactivation mechanism in a proportion of sporadic ccRCC cases. 
Another frequent event, described by Morris et al., is the methylation of the gene 
coding the transmembrane chemokine CXCL16 in RCC cell lines and in primary tumors 
but not in normal kidney (Morris et al., 2008). In addition to these genes many other TSGs 
have been investigated. Several adhesion molecules (e.g. CDH1, JUP, LSAMP), genes 
associated with apoptosis (e.g. APAF1, CASP8, DAPK1), cell cycle genes (e.g. CDKN2α), 
among others, have been described to be methylated in RCC, although revealing variable 
methylation frequencies (Baldewijns et al., 2008).  
Another reported event is the activation of the MN/CA9 gene that has been associated 
with hypomethylation in human renal cell carcinoma cell lines (Cho et al., 2000). 
Epigenetic alterations, particularly promoter methylation, are also an important class 
of cancer biomarkers. Costa et al. described in 2007 three differentially methylated cancer-
related genes, CDH1, PTGS2 and RASSF1A, in the four most prevalent renal cell tumor 
subtypes, ccRCC, pRCC, chrRCC and oncocytoma (Costa et al., 2007b).  
 
 
5. The PAX Gene Family 
 
The paired-box transcription factor family, encoded by developmental control genes, 
is mainly characterized by a highly conserved paired-box DNA-binding domain. This 
domain was initially identified in the Drosophila pair-rule segmentation gene paired (prd).  
Nine paired-box genes have been described until now (PAX1 to PAX9), which can be 
divided into four different subgroups. This classification is based on the gene sequence and 
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correlates with expression patterns in developing embryonic tissues (Chi and Epstein, 
2002).  
The temporal and spatial expression of PAX genes is tightly regulated as PAX 
proteins function as nuclear transcription factors essential not only for cellular 
differentiation, and migration, but also for cell proliferation. Since these genes are 
important transcriptional regulators it is likely that they are relevant targets for disruption 
during oncogenesis (Schafer, 1998). 
 
5.1 PAX2 Gene 
The PAX2 (Paired-box 2) gene encodes a transcription factor belonging to the 
evolutionarily conserved paired-box family. It is required during the development of the 
central nervous system and genitourinary tract (Torban et al., 2000), being expressed in the 
developing kidney as well as the optic stalk, midbrain-hindbrain junction, and the spinal 
chord (Chi and Epstein, 2002). 
 
5.1.1 Molecular characterization 
The PAX2 gene, along with PAX5 and PAX8, belongs to subgroup II of the PAX 
family and is located at locus 10q24.3-q25.1 (Figure 7).  
 
 
Figure 7: Chromosome 10 mapping. Red arrow indicates PAX2 gene location in chromosome 10. 
Adapted from Genetics Home Reference (Calvo et al., 2010). 
 
The PAX2 gene contains 12 exons (Sanyanusin et al., 1996), several of which are 
alternatively spliced. There are 5 well characterized alternative splice variants (variant 1 to 
5) which encode 5 different isoforms (isoforms a to e) (Figure 8). 
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Figure 8: PAX2 transcript variants.  
Adapted from (NCBI, 2010). 
 
Transcript variant e encodes the longest isoform. The variant b lacks an alternate in-
frame exon and uses an alternate splice site in the 3' coding region, compared to variant e 
resulting in a protein (isoform b) with a shorter, distinct C-terminus compared to isoform e. 
Variant a uses an alternate in-frame splice site in the 3' coding region, compared to variant 
e, resulting in a shorter protein (isoform a) that has a shorter, distinct C-terminus compared 
to isoform e. Variant c has multiple differences in the coding region, compared to variant e, 
one of which results in a translational frameshift. The resulting protein (isoform c) has a 
distinct C-terminus, with a proline-, serine-, threonine-rich portion, and is shorter than 
isoform e because it also lacks exon 6. Transcript variant d lacks an alternate in-frame exon 
compared to variant e. This results in an isoform (isoform d) that is shorter than isoform e 
(Ward et al., 1994). Importantly, all transcript variants share the same promoter region. 
 
5.1.2 The PAX2 protein 
The PAX2 protein is composed by 434 amino acid residues and has a nuclear 
localization. PAX proteins can mediate DNA binding and either transcriptional activation 
or repression through distinct domains. The PAX2 protein, specifically, has three distinct 
domains: an amino-terminal paired-box domain (PD), a conserved octapeptide domain 
(OP) and a proline-serine-threonine-rich carboxy-terminal transactivation domain (TD) 
(Figure 9, A). There is a fourth domain, the paired-type homeodomain (HD), which is 
truncated to a single helix among the proteins belonging to the subgroup II of PAX 
proteins, in which PAX2 is included (Figure 9, A and B) (Dressler et al., 1990; Eccles et 
al., 1992; Wang et al., 2008). 
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(A) 
 
 
(B)
 
Figure 9: (A) Structural representation of a PAX family protein containing the paired-domain (PD), 
the octapeptide motif (OP), the homeodomain (HD) and the transactivation domain (TD). In Chi and Epstein, 
2002. (B) Schematic representation of the structural domains of the PAX gene family groups, and their 
putative contribution to cancer. In (Robson et al., 2006). 
 
DNA binding activities are associated with the amino terminal paired-box domain, 
and transcription activation or repression are mediated by C-terminal domains of the PAX2 
protein (Lechner and Dressler, 1996). More specifically, the PD, composed of 128 amino 
acid residues, establishes high affinity sequence-specific interactions with DNA (Wang et 
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al., 2008). Structurally, this domain is composed of three α-helices, two of which are 
located near the carboxy end and the other near to the amino end of the domain (Stuart and 
Gruss, 1996). The OP motif is located between the PD and the HD (reduced to a single 
helix in PAX2). It has been described that this motif mediates transcriptional inhibition, 
thus acting like a repressor (Eberhard et al., 2000). The TD has also been shown to exert 
transcriptional regulation function (Chi and Epstein, 2002). 
The presence of both activation and repression domains in PAX2, as well as in the 
other PAX family members, suggests that these proteins have multiple functions that 
ultimately depend on the cellular context of target sequences (Dressler and Woolf, 1999). 
The proteins included in subgroups II (PAX2, PAX5 and PAX8) and III (PAX3 and 
PAX7) play key roles in human malignancies (Figure 9, B). The proteins included in both 
of these subgroups comprise an octapeptide domain (OP), and at least a partial 
homeodomain (HD), as can be seen in Figure 9, B. Therefore it would be plausible to 
postulate that both these domains may be involved in the interaction with a specific 
network of proteins and that this interaction might turn those genes more susceptible to 
inappropriate regulation within a tumor cell microenvironment (Robson et al., 2006). 
 
 
6. PAX2 in Kidney Development 
 
Three partially overlapping kidney systems are formed during human embryonic 
development: the pronephros, the mesonephros and metanephros. The first two systems are 
transient and the third persists as a functional kidney appearing in the 5th week of 
embryonic development in humans (Sadler, 2004). Like most organs, differentiation of the 
kidney involves epithelial-mesenchymal interactions. In this organ, the epithelium of the 
ureteric bud (UB) from the mesonephros interacts with mesenchyme of the metanephric 
blastema (Metsuyanim et al., 2008). 
In the first steps of the metanephros development, the metanephrogenic mesenchyme 
develops and induces the formation of epithelial branches, the ureteric buds. When the 
these emerge they enter the metanephric mesenchyme inducing this mesenchymal tissue to 
condense around them and differentiate into the nephrons (Figure 10). First, the tips of 
these branches induce the mesenchyme cells to form epithelial aggregates or vesicles, 
which will give rise to small S-shaped tubules (Gilbert, 2003). Then, capillaries grow into 
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the pocket at one end of the S and differentiate into glomeruli. The tubes derived from the 
mesenchyme form the secretory nephrons of the functional kidney and the branched 
ureteric bud gives rise to the renal collecting ducts and to the ureter. The tubules and the 
glomeruli constitute the nephrons. The proximal end of each of the nephrons forms the 
Bowman’s capsule that grows around the glomerulus. These two structures constitute the 
renal corpuscle. Continuous lengthening of the excretory tubule results in formation of the 
proximal convoluted tubule, loop of Henle and distal convoluted tubule (Sadler, 2004).  
 
 
Figure 10: Representative scheme of the developing kidney.  
(A) The two intermediate mesodermal tissues - the UB and the metanephrogenic mesenchyme – 
interact and induce each other to form the kidney; the metanephrogenic mesenchyme induces the UB to 
elongate and branch. (B) The tips of these branches cause the mesenchyme cells to aggregate. (C), (D) Each 
aggregated nodule first elongates and then forms a characteristic S-shaped tubule. (E), (F) The cells of this 
epithelial structure begin to differentiate into specific cell types to form the mature structure.  
Adapted from (Gilbert, 2003). 
 
Several genes have been identified that are expressed in the undifferentiated 
metanephric mesenchyme, and are required for appropriate differentiation of the 
metanephric kidney. These include PAX2, WT1 (Wilms tumor 1), EYA (Eyes absent 
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homolog 1), SIX2 (SIX homeobox 2), HOX11 (TLX1, T-cell leukemia homeobox 1), 
among others (Metsuyanim et al., 2008). 
Paired-box domain containing gene products are transcriptional factors and are thus 
capable of implementing a genetic program. These PAX proteins have been shown to play 
an essential role in early mammalian development (Stuart and Gruss, 1996). In the case of 
PAX2, specifically, both mRNA and protein can be detected in the pronephric duct, the 
earliest epithelial structure derived from the intermediate mesoderm. As the duct extends 
into the mesonephric region, PAX2 expression remains and becomes evident in 
mesonephric tubules. At the time of ureteric bud outgrowth and invasion into the 
metanephric mesenchyme, PAX2 expression is activated in mesenchymal cells with 
particular high levels in condensing mesenchyme at the UB tips, where it is thought to 
suppress apoptosis and promote epithelial aggregation. This process is critical to achieve 
the optimal nephron number at birth (Dziarmaga et al., 2006a). PAX2, together with WNT4 
(Wingless-type MMTV integration site family, member 4), causes the mesenchyme to 
epithelialize in preparation for tubule differentiation (Sadler, 2004). Thus, the PAX2 is one 
of the earliest markers for induced mesenchyme and may be activated by inductive signals 
that come from the bud (Dressler and Woolf, 1999). It seems that PAX2 also orchestrates 
the branching of the UB through activation of glial derived neurotrophic factor (GDNF) 
and its corresponding receptor (Brophy et al., 2001). 
The PAX2 expression, primarily seen during the early stages of development, seems 
to be switched off in the later phases of terminal differentiation, in the most part of the 
kidney structures. In fact, as the induced mesenchyme suffers epithelial conversion 
forming first the renal vesicle and then the S-shaped body, PAX2 expression is down-
regulated (Dressler and Woolf, 1999). In adult kidneys, PAX2 protein expression is 
restricted to collecting ducts, being almost undetectable in the proximal and distal tubules. 
PAX2 expression in collecting ducts protects medullary cells against the stress induced by 
high levels of NaCl and urea. The stress of hyperosmolality is a great stimulus for PAX2 
induction in the renal medulla in vivo (Cai et al., 2005). 
How PAX2 expression is suppressed at the end of embryogenesis in most of these 
structures remains unclear, but some data support that epigenetic silencing, mediated by 
PAX2 promoter methylation, occurs in the normal adult kidney cells of rats (Metsuyanim et 
al., 2008). 
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Germline mutations in PAX2 gene lead to developmental abnormalities in kidneys, as 
well as in other organs (Fletcher et al., 2005) revealing the important role of PAX2 in 
kidney development. 
 
 
7. PAX2 Protein Interactions 
 
There is evidence that PAX proteins’ function must be mediated by interactions with 
other nuclear proteins. These nuclear proteins should be able to complex with PAX2 at the 
DNA binding site and thus mediate activation or repression (Dressler and Woolf, 1999). 
McConnell and colleagues described that PAX2 binds to WT1 5’ regulatory 
sequences, and that these two proteins work by cross transcriptional control: at the early 
stages of renal development PAX2 modulates the transcriptional activity of WT1; at later 
stages, when a threshold level of WT1 is reached, it represses PAX2 transcription 
(McConnell et al., 1997). The Wilms tumor suppressor gene, WT1, is a transcription factor 
expressed in the fetal kidney condensed mesenchyme that makes this tissue competent to 
respond to induction by the UB. The bud induces the mesenchyme via FGF-2 (Fibroblast 
growth factor 2) and BMP-7 (Bone morphogenetic protein 7) (Sadler, 2004). 
Other researchers reported that activin, a dimeric protein, member of the TGFβ 
superfamily, is involved in the disruption of the ureteric bud branching, thus being a 
negative regulator of tubulogenesis, and reduces PAX2 expression in embryonic kidneys 
(Maeshima et al., 2002). 
Neuronal apoptosis inhibitor protein (NAIP) is an endogenous inhibitor of caspases 3 
and 7, expressed in the UB of the fetal kidney. Its expression pattern overlaps that of 
PAX2. Some studies showed that PAX2 binds directly to a motif in the NAIP promoter 
stimulating its transcription in vitro (Dziarmaga et al., 2006b). 
The BRCT-domain protein PTIP (PAX transcription activation domain interacting 
protein) links PAX2 to the H3K4 methylation machinery. PTIP is part of a histone H3K4 
methyltransferase complex that localizes to a PAX2 DNA binding sequence, in a PAX2 
dependent way, recruiting the ALR methyltransferase complex to the PAX2 binding site 
(Patel et al., 2007). Because PAX2 can be serine/threonine phosphorylated in response to 
Wnt signals, the interaction with PTIP promotes H3K4 methylation at kidney-specific loci 
in response to inductive signals (Dressler, 2008). 
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A recent study also suggested that the activation of PAX2 is stimulated by hypoxia 
and depends on the functional integrity of VHL in ccRCCs (Luu et al., 2009). These 
authors identified several putative hypoxia response elements by analyzing the PAX2 
promoter region, and showed that PAX2 activation is essentially regulated by HIF, 
although other tissue specific factors may be required for its expression in these tumors 
(Luu et al., 2009). 
 
 
8. PAX2 as a Proto-oncogene 
 
The oncogenic potential of the PAX genes family has been reported in vitro with 
transformation of cell cultures and in vivo with cell injections in nude mice (Maulbecker 
and Gruss, 1993).  
Several members of the PAX family, especially those corresponding to subgroup II 
and III, are involved in a number of human malignancies including renal tumors, 
lymphoma, thyroid medullary carcinoma, rhabdomyosarcoma and melanoma (Muratovska 
et al., 2003). PAX2 expression in particular, has been detected in primary tumor sections 
of brain, breast, ovarian, and lymphoid cancer (Muratovska et al., 2003). Other authors 
have also reported PAX2 expression in renal cell, endometrial and prostate carcinoma 
(Gnarra and Dressler, 1995; Wu et al., 2005; Bose et al., 2009).  
As previously stated, the expression of PAX2 protein is not observed in the mature 
renal structures, except for the collecting ducts. In Wilms tumors, a relatively common 
childhood neoplasm, and in some of the subtypes of renal cell tumors, re-expression of 
PAX2 can be detected by immunohistochemistry (Metsuyanim et al., 2008; Gupta et al., 
2009). In these RCT subtypes expressing PAX2, namely clear cell RCC, papillary RCC 
and oncocytoma, PAX2 expression may be part of the tumorigenic process representing a 
proliferation stimulus (Figure 11). On the other hand, failure to suppress PAX2 during 
embryonic development may predispose renal epithelial cells to further genetic lesions in a 
multistep oncogenic transformation pathway (Gnarra and Dressler, 1995). 
In fact, there is evidence supporting that PAX2 protects against caspase-2-induced 
apoptosis in renal collecting duct cells (Figure 11), which are those expressing PAX2 in 
normal adult kidneys (Torban et al., 2000), and suggest the involvement of PAX2 in cell 
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proliferation and differentiation to reconstruct tubular structure during regeneration after 
ischemic injury (Maeshima et al., 2002). 
 
Figure 11: Characteristics conferred by PAX2 gene, and other PAX family members, that promote 
tumor formation and/or progression. Adapted from (Robson et al., 2006). 
 
In 2006, Hueber and colleagues reported that PAX2 conferred resistance to cisplatin-
induced apoptosis. Cisplatin is a widely used anticancer drug that interacts with DNA 
forming adducts and therefore induces several signal transduction pathways that ultimately 
result in the activation of apoptosis (Hueber et al., 2006). Others have also reported that the 
expression of PAX2 by Kaposi’s sarcoma cells correlates with an enhanced resistance to 
vincristine-induced apoptosis and promotes invasive potential (Buttiglieri et al., 2004). 
All these data are in agreement with the already stated idea that PAX2 may act as an 
oncogene, by stimulating cell proliferation and/or by inhibiting apoptosis. These 
characteristics conferred by PAX2 gene are depicted in Figure 11. 
 
 
9. Methylation of PAX Genes 
 
Several members of the PAX genes family have been described to be aberrantly 
methylated in different cancer models. These genes are involved in numerous steps of 
carcinogenesis and may work either as TSGs or as proto-oncogenes. 
The promoter of PAX6, a gene coding for a DNA binding protein that participates in 
brain and eye development, has been described to be aberrantly methylated in early bladder 
cancer and in normal adjacent mucosa (Hellwinkel et al., 2008). Other investigators found 
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that this gene promoter was methylated in a tumor cell line and in primary tumors from 
follicular lymphoma (Bennett et al., 2009). 
The PAX5 gene belongs to the same PAX family group as PAX2 and participates in 
cell differentiation and embryonic development. This gene has also been reported to be a 
frequent target for aberrant methylation in tumor cell lines, as well as in primary tumors 
from breast and lung (Palmisano et al., 2003). 
PAX7 belongs to group III of PAX genes family, which is considered a tumor 
promoting group of genes. This gene has also been reported to be methylated in RL 
follicular lymphoma cell line (Bennett et al., 2009). 
Concerning PAX2, Wu and colleagues have described PAX2 promoter 
hypomethylation in endometrial carcinoma as being responsible for PAX2 re-expression in 
this type of cancer. These authors showed that the PAX2 promoter was methylated in 
normal endometrium and that this methylation was concomitant with lack of PAX2 
expression. On the other hand, endometrial carcinomas showed PAX2 promoter 
hypomethylation, and this state was correlated with PAX2 expression (Wu et al., 2005). 
Moreover, Metsuyanim et al. reported PAX2 hypermethylation in the adult kidney of rats 
coinciding with its silencing with the completion of nephrogenesis (Metsuyanim et al., 
2008). 
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AIMS OF THE STUDY 
 
According to the literature, significant expression of PAX2 protein occurs in three of 
the most prevalent renal cell tumor subtypes - clear cell RCC, papillary RCC and 
oncocytoma - but not in chromophobe RCC (Gupta et al., 2009). Moreover, PAX2 is 
considered an oncogene, suppressed at the later stages of embryonic development, possibly 
by promoter methylation (Metsuyanim et al., 2008), and reactivated during the 
carcinogenic process of some cancer models. Therefore, we hypothesized that PAX2 loss 
of expression in chromophobe RCC might be due to epigenetic silencing, through 
promoter methylation. 
On the other hand, both fluorescent in situ hybridization (FISH) (Brunelli et al., 
2005) and conventional cytogenetic (Memeo et al., 2007) analysis showed that 
chromosome 10 loss occurs in 40 to 60% of chromophobe RCC cases. Because PAX2 
locus maps to chromosome 10, gene deletion might constitute an alternative mechanism 
for gene downregulation. 
 
Hence, the main goal of this study was to identify epigenetic and/or genetic 
alterations affecting the PAX2 gene in a series of renal cell tumors, representing the four 
major subtypes: clear cell RCC, papillary RCC, chromophobe RCC, and oncocytoma. 
 
Specifically, the aims of this study were to: 
1. Analyze the expression of PAX2 in the different renal cell tumor subtypes, at 
mRNA level and at protein level. 
2. Determine whether the regulation of PAX2 expression occurs by epigenetic 
mechanisms, by assessing its promoter methylation status. 
3. Analyze the association between the number of PAX2 copies and its expression in 
a series of renal cell tumors.  
4. Evaluate the potential use of PAX2 epigenetic/genetic alterations as a biomarker 
for discrimination among RCC subtypes, specifically between chromophobe RCC and 
oncocytoma. 
MATERIALS AND METHODS 
29 
 
MATERIALS AND METHODS 
 
1. Biological Samples 
One hundred and twenty renal cell tumor samples comprising 30 cases of each of the 
four major subtypes (Clear Cell RCC, Papillary RCC, Chromophobe RCC, and 
Oncocytoma) were included in this study. These samples were consecutively selected from 
a larger series of patients diagnosed and treated at the Portuguese Oncology Institute – 
Porto, Portugal, who underwent partial or total nephrectomy, after informed consent. A 
small tumor sample was immediately snap-frozen, stored at -80ºC, and subsequently cut in 
a cryostat for nucleic acid (DNA and RNA) extraction. The bulk material was routinely 
fixed in buffered formalin and paraffin-embedded. The corresponding hematoxylin-eosin-
stained sections were examined by a pathologist to determine the tumor type (Eble et al., 
2004), grade classification (Fuhrman et al., 1982), and pathological stage according to the 
TNM staging system (Edge et al., 2010). A representative paraffin block of each tumor 
was further chosen for immunohistochemical and FISH analyses. 
For control purposes, four normal renal tissue samples, obtained from autopsies of 
patients without renal tumor were also selected. These were identified as normal kidney 
(NK) samples. 
Relevant clinical data was collected from patient’s clinical records. 
To serve as a putative positive control for PAX2 promoter methylation in tissue 
samples (Wu et al., 2005), five samples of formalin-fixed, paraffin-embedded normal 
endometrium, collected from women submitted to hysterectomy for uterine leiomyomas, 
were also randomly selected for this study. 
These studies were approved by the institutional review board (Comissão de Ética) 
of Portuguese Oncology Institute – Porto. 
 
 
 
 
 
 
MATERIALS AND METHODS 
30 
 
2. Methods 
 
2.1 Assessment of PAX2 protein expression  
 
2.1.1 Immunohistochemistry 
Immunohistochemistry was performed according to the avidin-biotin method using 
the VECTASTAIN® Universal Elite ABC Kit [©Vector Laboratories, Burlingame, CA, 
USA]. 
Four micron-thick sections from the representative paraffin block of each renal cell 
tumor and of the five normal endometrium samples were placed in StarFrost® Adhesive 
slides [Knittel-Gläser, Germany]. The slides were deparaffinized with xylene and 
rehydrated with 100%, 90% and 70% ethanol solutions, and subsequently steamed in a 1x 
sodium citrate buffer solution [©Vector Laboratories, Burlingame, CA, USA] for 20 
minutes in a 700 W microwave oven for antigen retrieval. Every 5 minutes, cool distilled 
water was added to avoid tissue detachment. At the end of this process, slides were cooled 
for 10 minutes in cool distilled water. Endogenous peroxidase was blocked by incubating 
the slides in a 0.6 % H2O2 solution for 20 minutes. After washing the slides in distilled 
water and PBS (Phosphate Buffered Saline)/tween 20 solution they were incubated with 
Normal Horse Serum 1:100 in PBS-Bovine Serum Albumin (BSA) for 30 minutes, in a 
humid chamber, at room temperature, to avoid antibody unspecific links. Then, the slides 
were incubated with the primary antibody for 18 hours, at 4º C, in a humid chamber. A 
rabbit monoclonal PAX2 antibody [Abcam, UK] was used in a 1:3000 dilution. The slides 
were next incubated with the biotynilated secondary antibody 1:100 in PBS/BSA for 30 
minutes in a humid chamber, at room temperature. 
Localization was performed by the standard avidin-biotin-immunoperoxidase 
method, by incubating the sections with the ABC complex 1:100 in PBS/BSA for 45 
minutes, in a humid chamber, at room temperature. The slides were then immersed in a 
3.3’-diaminobenzidine solution for 7 minutes, which functioned as the chromogen. After 
washing the slides in tap water they were counterstained with hematoxylin for 10 seconds 
and once again washed in tap water. 
Finally, the sections were dehydrated using increasing ethanol concentrations (70%, 
90% and 100%) and xylene, and the slides were mounted with Entellan® [Merck, 
Germany]. 
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An unrelated clear cell RCC section showing intense immunoreactivity for PAX2 
protein, was used as positive control. The negative control consisted on the omission of the 
primary antibody. 
 
2.1.2 Scoring of immunohistochemistry staining 
Following a low-magnification screening of the whole slide, multiple (generally 15 
to 20) high-magnification microscopic fields were examined in each case to asses PAX2 
expression. The immunoreactivity of nuclei from cells of the distal tubule and of the 
collecting duct of normal renal tissue adjacent to each tumor was used as internal positive 
control. The results of PAX2 expression in each tumor were expressed in a 
semiquantitative way according to the estimated percentage of positive tumor cells. 
Immunostaining of more than 10% of the tumor cell nuclei was required for scoring a case 
as positive. The positive cases were further divided in two categories according to the 
proportion of positive cells (Table 2). These criteria have been previously used by other 
researchers (Mazal et al., 2005; Memeo et al., 2007; Gupta et al., 2009) 
 
Table 2: Scoring of immunohistochemistry staining results. 
Proportion of positive cells  Score 
≤ 10% Negative 0 
>10% - 50% 
Positive 
1 
> 50% 2 
 
 
2.2 Nucleic acid extraction and quantification 
2.2.1 DNA from renal tissues 
DNA from RCT and NK samples was extracted by the phenol-chloroform method, at 
pH 8, as previously described (Pearson and Stirling, 2003). Briefly, the samples were 
digested by adding 2700 µL of buffer solution SE (75 mM NaCl; 25 mM EDTA), 300 µL 
of sodium dodecyl sulfate (SDS) 10% and 25 µL of proteinase K, 20 mg/mL [Sigma-
Aldrich®, Germany] to each tissue sample, which were then placed in a bath at 55ºC, and 
incubated overnight. If necessary, the incubation went on for two or three additional days, 
and more proteinase K was added every day. After digestion, extraction was performed 
with phenol/chloroform [Sigma-Aldrich®, Germany; Merck, Germany] in Phase Lock 
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Gel™ Light tubes [5Prime, Germany]. The digested samples were transferred to these 
tubes containing the phenol/chloroform mixture and centrifuged for 20 minutes at 4000 
rpm. Then, the upper aqueous phase was transferred to a new tube and the DNA 
precipitation followed with 6 mL of 100% cold ethanol and 1 mL of ammonium acetate 7.5 
M [Sigma-Aldrich®, Germany]. Each sample was gently mixed and incubated overnight at 
-20ºC to improve DNA precipitation. Finally, the samples were washed twice with a 70% 
ethanol solution and then eluted in sterile distilled water [B. Braun, Melsungen, Germany].  
DNA quality and concentration were analyzed in a spectrophotometer NanoDrop 
ND-1000 [NanoDrop Technologies, USA]. Eluted samples were stored at -20ºC. 
 
2.2.2 RNA from the renal tissues  
RNA from RCT and NK samples was extracted using the PureLink™ RNA Mini Kit 
[Invitrogen, CA, USA] according to the manufacturer’s instructions. Briefly, 500 µL of 
Lysis buffer containing 1% of β-mercaptoethanol [Sigma-Aldrich®, Germany] were added 
to each sample and homogenized using a Rotor-stator homogenizer [VWR™, USA] for 
45-90 seconds. An additional 500 µL of this solution were added to the samples. The 
samples were then centrifuged at 5000 rpm, at 4ºC for 5 minutes and the supernatant 
transferred into a new tube. Equal volume of ice cold 75% ethanol solution was added to 
the samples. The resulting mixture was vigorously shaked by hand and 700 µL of this 
solution were next transferred to a spin cartridge, which was previously placed in a 
collection tube. The tubes were centrifuged at 11000 rpm at room temperature, for 15 
seconds. This process was repeated until all of the solution was processed. The samples 
were washed with 700 µL of Wash Buffer I and then with 500 µL of Wash Buffer II. This 
last washing step was repeated once. Then, the collection tube was discarded and the spin 
cartridge placed in a recovery tube. RNase-free water (2x 30 µL) was added to each spin 
cartridge and the tubes were centrifuged to allow for RNA elution.  
RNA quantification and quality assessment were performed in a spectrophotometer 
NanoDrop ND-1000 [NanoDrop Technologies, USA]. RNA from each sample was also 
loaded on a 2% agarose gel to assess for integrity. Bands corresponding to both 18s and 
28s rRNA should be visible in the agarose gel to consider the sample suitable for further 
analysis. The RNA samples were then stored at -80ºC. 
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2.2.3 DNA from formalin-fixed paraffin embedded normal endometrium tissues 
DNA was extracted using the QIAamp® DNA FFPE Tissue Kit [QIAGEN, 
Germany] according to the manufacturer’s instructions. Briefly, tissue sections were first 
deparaffinized and rehydrated using xylene and ethanol 100%. After this treatment, 
supernatant was removed by pippeting and samples were left to dry at room temperature 
until all residual ethanol was evaporated. The pellet was then ressuspended in 180 µL of 
ATL Lysis Buffer and 25 µL of proteinase K, and incubated at 55ºC overnight. 
On the next day, samples were incubated for one hour at 90ºC to reverse 
formaldehyde modification of nucleic acids. After incubation, 200 µL of AL Lysis Buffer 
and 200 µL of 100% ethanol were added to the samples, and the samples were vortexed. 
The resulting lysate was transferred to the QIAamp MinElute column and the tubes were 
centrifuged at 8000 rpm for 1 minute. The column was then washed with 500 µL of AW1 
Wash Buffer by centrifuging the tubes for 1 minute at 8000 rpm. The process was repeated 
with 500 µL of AW2 Wash Buffer. The column was placed in a recovery tube and 50 µL of 
warm water (heated at 90ºC) were added to the column to elute the DNA. After 5 minutes 
of incubation the tubes were centrifuged at 14000 rpm for 5 minutes. DNA quantification 
and quality assessment were performed as previously described for renal tissues. Samples 
were stored at -20ºC.  
 
2.3 Assessment of PAX2 mRNA expression 
Quantitative reverse-transcription (qRT)-PCR was performed to assess PAX2 
expression. First, the extracted RNA was transcribed into cDNA which was then used as 
template for the PCR reaction. 
The housekeeping gene hypoxanthine phosphoribosyltransferase 1 (HPRT1) was 
used as an endogenous control, to normalize for the input of template cDNA. 
Quantitative expression of both endogenous control and target genes was determined 
using Taqman® Gene Expression Assays [Applied Biosystems, CA, USA]. 
  
2.3.1 cDNA synthesis from  the extracted RNA 
cDNA was synthesized by reverse transcription using the RevertAid™ H Minus First 
Strand cDNA synthesis Kit [Fermentas, Ontario, USA], according to the manufacturer’s 
instructions. Briefly, 1 µL of Random hexamer was added to 500 ng of template RNA. 
This mixture was incubated at 70ºC for 5 minutes to allow for RNA denaturation. The 
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following components were then added: 2 µL of 5x Reaction Buffer, 0.5 µL of Ribolock 
RNase inhibitor (20 U/ µL) and 1 µL of 10 mM dNTP mix, and the samples were 
incubated at 25ºC for 5 minutes. Finally, 0.5 µL of RevertAidTM H Minus M-MuLV 
Reverse Transcriptase (200 U/ µL) were added and reacted under the following conditions: 
25ºC for 10 minutes, 42ºC for 60 minutes and 70ºC for 10 minutes. 
The newly synthesized cDNA samples were eluted in 100 µL of DEPC water [MP 
Biomedicals, OH, USA] and stored at -20ºC. 
 
2.3.2 Quantitative PAX2 expression analysis 
Quantitative PAX2 expression analysis was performed using Taqman® technology. 
The Taqman® assays are based on the FRET (Förster/Fluorescence Resonance Energy 
Transfer) technology and use a fluorogenic probe to enable detection as DNA copies 
accumulate during PCR cycles. TaqMan® probes consist of a fluorophore covalently 
attached to the 5’-end of the oligonucleotide probe and a quencher at the 3’-end. During 
amplification, the Taq polymerase cleaves the reporter from the probe, owing to its 5’-3’ 
exonuclease activity, releasing it from the quencher and promoting its detection. 
In this study, two Taqman® Gene Expression Assays were used. These are pre-
designed optimized real-time PCR assays for gene expression quantification: 
- For HPRT1, a Gene Expression Assay specific for HPRT1 exons 6 and 7 (Hs 
99999909_m1, [Applied Biosystems, CA, USA]) was used. 
- For PAX2, a Gene Expression Assay specific for exons 1 and 2 (Hs01057413_m1, 
[Applied Biosystems, CA, USA]) was used. 
The reactions were carried out in 96-well plates on an Applied Biosystems 7500 
Real-time PCR system [Applied Biosystems, CA, USA], using the following conditions: 
50 ºC for 2 minutes, 95 ºC for 10 minutes and 45 amplification cycles at 95 ºC for 15 
seconds and 60 ºC for 1 minute. 
In each reaction, 9 µL of cDNA, 1 µL of Taqman® Gene Expression Assay and 11 
µL of Taqman® Gene Expression Assay Master Mix [Applied Biossystems, CA, USA] 
were used. All samples were run in triplicate. Two negative controls, consisting on the 
replacement of cDNA with DEPC-treated water [MP Biomedicals, OH, USA], were 
included in each plate. 
The standard curve method was used for quantitation. This curve was built with a 
series of cDNA dilutions prepared from commercial Stratagene® QPCR Human Reference 
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total RNA [Agilent Technologies, Stratagene, CA, USA] or from a PAX2 expressing renal 
cell tumor (oncocytoma), for HPRT1 and PAX2 analysis, respectively. PAX2 expression 
levels were calculated by dividing the values of PAX2 by those of the respective 
endogenous control values (HPRT1), obtained from qRT-PCR (mean quantity). This ratio 
was then multiplied by 1000 for easier tabulation. 
 
2.4 Methylation analysis 
Methylation analysis was performed using the methylation-specific PCR (MSP) 
method. This is a simple, sensitive and rapid method to determine the methylation patterns 
from small samples of DNA, allowing for the distinction between methylated and 
unmethylated alleles. This method requires testing with two pairs of primers which amplify 
methylated or unmethylated gene sequences in previously bisulfite-modified DNA.  
 
2.4.1 Bisulfite modification of genomic DNA 
All DNA samples (from RCTs, NKs and normal endometrium) were subjected to 
sodium bisulfite modification. This method allows for the subsequent evaluation of the 
methylation status of individual CpG dinucleotides in genomic DNA. During this reaction, 
the bisulfite converts all cytosine residues to uracil residues, excepting those that are 
methylated (5-mC). These methylated cytosine residues are resistant to the modification 
and remain unchanged. This method implies sulfonation and deamination of cytosines, 
converting them to uracil sulfonate. A subsequent desulfonation is necessary to complete 
the conversion into uracil. Bisulfite modification was performed using the EZ DNA 
Methylation-Gold™ Kit [Zymo Research, Orange, CA, USA] according to the 
manufacturer’s instructions. Briefly, 1 µg of genomic DNA from each sample in a total of 
20 µL was mixed with 130 µL of CT conversion reagent and then reacted under the 
following conditions: 98 oC for 10 minutes and 64 oC for 150 minutes. This mixture was 
then mixed with 600 µL of M-binding buffer already placed in a Zymo-Spin ICTM cartridge 
and centrifuged at 10000 rpm for 30 seconds. The spin cartridge was washed with 100 µL 
of M-Wash buffer and centrifuged once again at 10000 rpm for 30 seconds. Subsequently, 
the samples were incubated with 200 µL of M-Desulphonation Buffer for 20 minutes at 
room temperature, to allow the removal of desulphonation residuals. The spin cartridge 
was then centrifuged at 10000 rpm for 30 seconds and two more washes with 200 µL M-
Wash buffer were performed. Finally, the spin cartridge was placed in a recovery tube and 
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the samples were eluted in 30 + 30 µL of distilled water [B. Braun, Melsungen, Germany]. 
Eluted samples were stored at -50ºC. 
 
2.4.2 Methylation analysis of PAX2 promoter 
Bisulfite-modified genomic DNA was tested using two sets of primers, each 
recognizing either the methylated or the unmethylated sequences located in the promoter 
region of the PAX2 gene. Two adjacent regions were screened to assess the promoter 
methylation status. Primer sequences are summarized in Table 3, along with amplicon 
lengths and positions, and optimized annealing temperatures. Primers were provided by 
Metabion, Germany. 
 
Table 3: Sequences of the primers used in the methylation-specific PCR experiments, amplicons size 
(AS), amplicons location in relation to the transcriptional start site (AL), and optimized annealing 
temperatures (AnT). 
Primer 
Primer sequence 
(5’ – 3’) 
AS 
(bp) 
AL 
AnT 
(ºC) 
Reference 
PAX2_M (F1) GGGTTTTTTTCGTCGAAGTTC 
170 -676 to -846 60 (Wu et al., 2005) 
PAX2_M (R1) ACTAAAACCTCGACTCCCGAT 
PAX2_U (F1) GGTTTTTTTTGTTGAAGTTTGG 
172 -673 to -845 62 (Wu et al., 2005) 
PAX2_U (R1) AAAACTAAAACCTCAACTCCCAAT 
PAX2_M (F2) AGTTGTTAGCGTCGTTCGGTTT 
139 -489 to -628 62 
(Metsuyanim et 
al., 2008) 
PAX2_M (R2) ACAATCCCGAAAATATCCGAAATAA 
PAX2_U (F2) AGAGTTGTTAGTGTTGTTTGGT 
141 -489 to -630 59 - 
PAX2_U (R2) ACAATCCCAAAAATATCCAAAAT 
M - Methylated, U – Unmethylated, F – Forward; R – Reverse; bp – base pairs 
 
The PCR reactions were performed in an Applied Biosystems Veriti® Thermal 
Cycler [Applied Biosystems, CA, USA]. Each PCR tube contained 14.36 µL of sterile 
distilled water [B. Braun, Melsungen, Germany], 2 µL of 10x DyNAzyme™ Hot Start 
Reaction Buffer [Finnzymes, Finland], 0.2 mM of dNTPs [Fermentas, Ontario, Canada], 
250 nM of primer forward and 250 nM of reverse primer, 0.24 µL of DyNAzyme™ II Hot 
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Start DNA polymerase 2U/µL [Finnzymes, Finland], and 2 µL of sample DNA, to a final 
volume of 20 µL. 
The PCR amplifications were performed as follows: ten-minute 94ºC incubation was 
followed by 38 cycles of 30 seconds at 94ºC, 30 seconds at annealing temperature (see 
Table 3) and 30 seconds at 72ºC. A ten-minute elongation step at 72ºC completed the PCR 
amplification. The PCR products were then separated on a 2% agarose gel.  
Primers specificity was assessed using CpGenome™ Universal Methylated DNA 
[Millipore, CA, USA] and CpGenome ™ Universal Unmethylated DNA [Millipore, CA, 
USA] as positive and negative controls, respectively. 
 
2.5 Fluorescent in situ hybridization analysis 
The aim of this technique is to identify either imbalances in the form of gains or 
losses of chromosome segments, or to detect specific breakpoints with or without 
imbalances. Thus, it can be defined as the morphological localization of genetic sequences, 
by determining the presence or absence of specific RNA or DNA species. The 
identification of these sequences is based on the property of nucleic acids to anneal to one 
another in a specific manner to form hybrids. Therefore, by labeling one of these strands, 
the hybrids can be detected by several means, including fluorescent methods. 
The basic requirements of this technique are therefore: a probe that is specific for the 
sequence of interest, fluorescent labeling of this probe to allow detection and a biological 
specimen with preservation of sufficient morphological detail to determine the localization 
of the labeled probe after hybridization (Kjeldsen and Kølvraa, 2002). 
For this particular study, Bacterial Artificial Chromosome (BAC) clones targeting 
the PAX2 gene (RP11_1061B5) were selected using the UCSC Human Genome Browser 
and obtained from the BACPAC Resources Center [Oakland, USA]. The extracted plasmid 
DNA containing an insert complementary to the target sequence was subsequently labeled 
with a fluorochrome and then used as a probe to perform FISH analysis. 
 
2.5.1 Bacteria growth 
The E. coli bacteria were first grown in LB (Luria-Bertani broth) agarose medium, 
supplemented with cloramphenicol 12.5 mg/mL, overnight at 37ºC. On the next day, an 
individual colony was inoculated in 10 mL of liquid LB medium and incubated at 37ºC, for 
16 hours with vigorous agitation.  
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The tube containing the E.coli LB culture was then centrifuged at 4000 rpm for 30 
minutes. The supernatant was discarded and the pellet used for plasmid DNA extraction. 
 
2.5.2 Plasmid DNA isolation 
Plasmid DNA was extracted using the NucleoSpin® Plasmid [Macherey-Nagel, 
Germany], according to manufacturer’s instructions. Briefly, the first step consisted in 
resuspending the cell pellet using 250 µL of Buffer A1. Then 250 µL of lysis Buffer A2 
were added and mixed gently with the sample, and incubated for up to 5 minutes at room 
temperature. Next, 300 µL of neutralization Buffer A3 were added and mixed gently by 
inverting the tube. The sample was subsequently centrifuged for 12 minutes at 10500 rpm 
at room temperature, to clarify the lysate. The resulting supernatant was placed in a 
NucleoSpin® Plasmid column and centrifuged at 10500 rpm for 1 minute. The flow-
through was discarded and 600 µL of wash Buffer A4 were added to the column which was 
centrifuged at 10500 rpm for 1 minute. The column was once again centrifuged at 10500 
rpm for 2 minutes to dry the silica membrane. Next, the column was placed in a new tube 
and 60 µL of elution Buffer AE were added, and incubated for 1 minute at room 
temperature to elute the DNA. Finally, the column was centrifuged at 10500 rpm for 1 
minute and DNA quality and concentration were analyzed in a NanoDrop ND-1000 
spectrophotometer [NanoDrop Technologies, USA].  
 
2.5.3 Plasmid DNA amplification 
Plasmid DNA was amplified before labeling to produce more copies of the sequence 
targeting the gene of interest. 
The plasmid DNA concentration was adjusted to 10 ng/µL to allow amplification 
using the Illustra GenomiPhi V2 DNA Amplification Kit [GE Healthcare, US]. Briefly, 1 
µL of template DNA was mixed with 9 µL of Sample Buffer. The template DNA was then 
denatured by heating the sample at 95 ºC for 3 minutes. Next, 9 µL of Reaction Buffer and 
1 µL of Enzyme Mix were added to the sample, and the mixture was placed in a 
thermocycler under the following conditions: 16 cycles at 30 ºC for 60 minutes, and 65 ºC 
for 10 minutes. The samples were stored at -20ºC. 
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2.5.4 Nick translation reaction 
Labeling of probes was performed using an enzymatic method called nick-
translation. This reaction employs two enzymes, deoxyribonuclease I (DNaseI) and DNA 
polymerase I. The DNase I hydrolyses nicks in each strand of the DNA molecule at 
random, and DNA polymerase removes individual base pairs from the nick in the 5’ to 3’ 
direction (exonuclease function), adds new nucleotides from the 3’ nick copying the 
template in the opposite DNA strand (polymerase function) and has also a 3’ to 5’ proof-
reading activity. In this way, labeled nucleotides are incorporated into the newly 
synthesized DNA (Schwarzacher and Heslop-Harrison, 2000). 
The nick translation reaction was performed as follows. Firstly, 1.5 µL of the 
amplified DNA was mixed with 30 µL of sterile bi-distilled water [B. Braun, Melsungen, 
Germany] and heated at 90ºC for 5 minutes to allow DNA denaturation. Then, 5 µL of 
nucleotide mix, 1.5 µL of Spectrum Green-dUTP [Enzo Life Sciences, USA], 1 µL of 
Polymerase I [Invitrogen, CA, USA], 10 µL of Polymerase I/DNase [Invitrogen, CA, 
USA] and 1 µL of MgCl2 [Sigma-Aldrich®, Germany] were added to the diluted DNA. 
This mixture was incubated in a thermocycler at 15ºC for 45 minutes and then at 70ºC for 
15 minutes, to allow the enzymes to function properly. 
At the end of this incubation the DNA was precipitated using 7.5 µL of sodium 
acetate, and 140 µL of 100% ethanol. Fifteen µL of Human Cot DNA [Invitrogen, CA, 
USA] were also added to avoid unspecific probe hybridization. The products were placed 
at -20ºC overnight to improve DNA precipitation. 
On the next day, samples were centrifuged at 14000 rpm for 30 minutes, then the 
supernatant was eliminated and the pellet was dried for 1 hour in the dark. The DNA was 
finally eluted in 10 µL of Vysis LSI/WCP Hybridization Buffer [Abbott Molecular, 
Illinois, USA] and mixed with 1 µL of a Vysis centromeric probe for chromosome 10, 
labelled with SpectrumOrange [Abbott Molecular, Illinois, USA]. These probes were 
stored at -20ºC. 
Adequate mapping and probe specificity was confirmed by hybridization onto 
normal human metaphases. 
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2.5.5 Sample processing 
The thirty chromophobe RCC samples were tested. 
Four-micron thick sections from formalin-fixed, paraffin-embedded tissues, placed in 
StarFrost® Adhesive slides (Knittel-Gläser, Germany) were first deparaffinized in two 
series of xylene followed by two series of 100% ethanol, and then rinsed in a 2x SSC 
[Vysis, Downers Grove, IL, USA] buffer solution twice, for 2 minutes each. The slides 
were then placed in a sodium thiocyanate (NaSCN) [Sigma-Aldrich, Germany] solution, 
for 15 minutes at 80ºC and rinsed once again in a 2x SSC buffer solution. The tissue was 
digested with 100 µL of a 4mg/mL pepsin solution for 6 minutes at 37ºC. After this 
incubation step, the slides were rinsed in a 2x SSC buffer solution and then dehydrated 
with increasing ethanol concentrations and dried at room temperature before staining. 
The sections were incubated with a mixture of the two probes, including the one 
designed to hybridize with the PAX2 gene, labeled with SpectrumGreen, and a centromeric 
probe for chromosome 10, labeled with SpectrumOrange [Vysis, Abbott Laboratories, 
Illinois, USA], and placed in a ThermoBrite® Denaturation/Hybridization System [Abbott 
Molecular, Illinois, USA], for 8 minutes at 80ºC and 18 hours at 37ºC, to allow co-
denaturation and probe hybridization, respectively. Following this hybridization, slides 
were washed in a 2x SSC/0.5% Igepal [Sigma-Aldrich, Germany] solution, at 73ºC for 5 
minutes and then in a 2x SSC/0.1% Igepal solution at room temperature for 3 minutes. 
Slides were counterstained with Vectashield Mounting Medium for Fluorescence 
with DAPI (4’,6-diamidino-2-phenylindole) [Vector Laboratories, Burlingame, CA, USA] 
and fluorescent images corresponding to DAPI, SpectrumGreen and SpectrumOrange were 
sequentially captured with a Cohu 4900 CCD camera, with the use of an automated filter 
wheel coupled to a Zeiss Axioplan fluorescence microscope [Zeiss, Oberkochen, 
Germany] and a CytoVision system version 2.7 [Applied Imaging, Santa Clara, CA, USA]. 
 
2.5.6 FISH scoring 
For scoring purposes, only intact, non-overlapping nuclei were considered. An 
abnormal population was considered representative when at least 10% of the neoplastic 
cell nuclei presented a copy number change. 
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2.6 Statistical analysis 
The chi-square test or Fisher’s exact test were used to seek for differences in the 
frequency of immunoreactivity for PAX2 protein according to the immunohistochemical 
scoring, among the four renal cell tumor types. These tests were also used to search for 
differences in the frequencies of immunoreactivity for PAX2 protein among the different 
pathological tumor stages and Fuhrman grades. Moreover, the directional measure 
Somers’d was computed. Somers’d statistics varies from -1 to 1 and assesses the 
association between two ordinal variables. Values near 1 reveal a strong positive 
association, whereas values near -1 reveal a strong negative association. 
To assess the value of PAX2 protein immunohistochemical expression for the 
discrimination of chromophobe RCC from oncocytoma, the sensitivity, specificity, positive 
and negative predictive values (PPV and NPV) were determined using the 10% or the 50% 
cutoff values. 
The median and the interquartile range of PAX2 mRNA expression levels for each 
subtype of renal cell tumor were determined. Differences among the four groups were 
assessed by the Kruskal-Wallis non-parametric test, followed by pairwise comparisons 
(ccRCC vs. chrRCC; pRCC vs. chrRCC; oncocytoma vs. chrRCC; ccRCC vs. pRCC; 
ccRCC vs oncocytoma; pRCC vs. oncocytoma) using the Mann-Whitney U test, when 
appropriate. The association between between PAX2 mRNA expression levels and the 
protein expression (immunohistochemistry score) was carried out using the Mann-Whitney 
test. 
The relationship between PAX2 mRNA expression levels and clinicopathological 
variables, such as tumor grade and stage, were evaluated using the Kruskal-Wallis test, 
followed by a Mann-Whitney U test, whereas the correlation between PAX2 expression 
levels and patients’ age was assessed by the Spearman non-parametric correlation test. 
The relationship between FISH findings and immunoexpression results for chrRCC 
was assessed by a chi-square or Fisher’s exact test, and the directional measure Somers’d 
was also computed. Moreover, the association between FISH findings and PAX2 mRNA 
levels for chrRCC was estimated using the Kruskal-Wallis test. 
The level of significance was set at p < 0.05 and the Bonferroni’s correction was 
used when appropriate. All tests were two-sided. 
Statistical analysis was performed with SPSS for Windows, version 15.0 [SPSS, 
Chicago, IL, USA]. 
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RESULTS 
 
1. Clinicopathological data 
 
Relevant clinical and pathological features of the patients included in this study are 
summarized in Table 4. Although this is not a consecutive but a selective series of patients, 
males were more frequently diagnosed with renal cell tumor and the median age at 
diagnosis was 59 years. 
 
Table 4: Clinical and pathological features of patient population. 
*Includes RCC cases only. 
 
 
 
 
Clinicopathological features RCT 
Patients, n 120 
Gender, n (%)  
Male 70 (58) 
Female 50 (42) 
Median age, yrs (range) 59 (29 - 83) 
Pathological stage*, n (%)  
I 50 (56) 
II 22 (24) 
III 16 (18) 
IV 2 (2) 
Furhman grade*, n (%)  
1 2 (2) 
2 29 (32) 
3 39 (44) 
4 20 (22) 
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2. PAX2 expression 
 
2.1 Protein expression 
To characterize PAX2 protein expression in renal cell tumors, immunohistochemical 
analysis was performed. As expected, immunoreactivity for PAX2 was found in cell nuclei 
only. 
In general, normal renal tissue did not show immunoreactivity for PAX2, with the 
exception of distal tubules and collecting duct cells which presented intense and 
homogeneous staining (Figure 12, A). 
Concerning tumor cells, staining was more intense in ccRCC and oncocytomas, as 
well as in pRCC type 1 (Figure 12, B, F and C). The vast majority of ccRCC and 
oncocytoma were considered positive, whereas most of chrRCC were negative (Figure 12, 
E). Concerning pRCC, positive cases were slightly more prevalent. The results of 
immunostaining scoring for PAX2 are summarized in Table 5. 
Concerning normal endometrium samples, immunostaining was apparent in all 
nuclei of endometrial glands (Figure 12, G) of the tested cases (n= 5). 
 
Table 5: Immunohistochemical expression of PAX2 in histologic sections of renal cell tumors. 
RCT Subtype 
Negative, n (%) Positive, n (%) 
≤10% >10 – 50% >50% 
Clear cell 1 (3.3) 4 (13.4) 25 (83.3) 
Papillary 13 (43.3) 4 (13.4) 13 (43.3) 
Type 1 6 (60) 0 (0) 4 (40) 
Type 2 7 (35) 4 (20) 9 (45) 
Chromophobe 20 (66.7) 6 (20) 4 (13.3) 
Oncocytoma 3 (10) 5 (16.7) 22 (73.3) 
 
 
RESULTS 
44 
 
 
 
 
Figure 12: Nuclear expression of PAX2.  
(A) Normal kidney (immunostaining is present in 
distal convoluted tubules and collecting ducts); 
(B) Clear-cell renal cell carcinoma; (C) Papillary 
renal cell carcinoma, type 1; (D) Papillary renal 
cell carcinoma, type 2; (E) Chromophobe renal 
cell carcinoma; (F) Renal oncocytoma; (G) 
Normal endometrium (immunostaining is present 
in endometrial glands). 
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The chi-square test detected significant differences in PAX2 expression among the 
four subtypes of renal cell tumors (p < 0.001). Pairwise comparisons disclosed significant 
differences in all cases (p < 0.01) except for pRCC vs. chrRCC (p = 0.119) and for 
oncocytoma vs. ccRCC (p = 0.612).  
Moreover, no significant differences in PAX2 expression were found between type 1 
and type 2 pRCC, using either the 10% (p = 0.270) or the 50% cutoff values (p = 1).  
 
Because the morphological differential diagnosis between chrRCC and oncocytoma 
is sometimes troublesome, we tested whether PAX2 immunostaining might be used as an 
ancillary tool for histopathological assessment. We also determined the performance of 
PAX2 immunoexpression for discriminating chrRCC from oncocytoma in previously 
published studies. These results are summarized in the same table (Table 6). 
 
Table 6: Performance of PAX2 immunoscoring for the discrimination between chromophobe RCC 
and oncocytoma, in this study and in previously published reports (Se: Sensitivity; Sp: Specificity; PPV: 
Positive predictive value; NPV: negative predictive value). 
 Se (%) Sp (%) PPV (%) NPV (%) 
Present study     
10% cutoff 67 90 87 73 
50% cutoff 87 73 76 85 
Gupta et al. 2009     
10% cutoff 94 100 100 85 
50% cutoff 94 65 89 79 
Mazal et al. 2005     
10% cutoff 91 10 50 54 
50% cutoff 100 3.5 51 100 
Memeo et al. 2007     
10% cutoff 91 87 77 95 
 
 
Concerning the clinicopathological data, we found significant differences between 
the immunoexpression frequencies according to pathological stage (p = 0.03) and Furhman 
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grade (p = 0.04). These results are shown in Table 7 and Table 8, respectively. Both stage 
and grade were grouped in 2 categories for statistical purposes. 
 
Table 7: Correlation between PAX2 immunoexpression and pathological tumor stage, n (%). 
 Immunoexpression scoring 
P 
 ≤ 10% > 10% 
Stages 1 & 2 23 (32%) 49 (68%) 
0.03 
Stages 3 & 4 11 (61%) 7 (39%) 
 
 
Table 8: Correlation between PAX2 immunoexpression and Furhman nuclear grade, n (%). 
 Immunoexpression scoring 
P 
 ≤ 10% > 10% 
Grades 1 & 2 7 (23%) 24 (77%) 
0.04 
Grades 3 & 4 27 (46%) 32 (54%) 
 
Moreover, Somers’d directional measure revealed a slightly, though significant, 
negative association between the immunoexpression frequency and pathological tumor 
stages (d = -0.236, p = 0.031) or Furhman grades (d = -0.227, p = 0.021). 
 
 
2.2 Quantitative mRNA expression 
A quantitative analysis was performed to assess PAX2 mRNA gene expression in the 
four renal cell tumor subtypes, and the results are displayed in Figure 13. 
 
RESULTS 
47 
 
 
Figure 13: Boxplot of the relative mRNA expression levels (Log 10 transformed) of PAX2 in clear 
cell RCC, papillary RCC, chromophobe RCC, and oncocytoma (n=120). 
 
The distribution of PAX2 mRNA expression levels according to the renal cell tumor 
subtype is displayed in Table 9. The Kruskal-Wallis test detected significant differences 
among the renal cell tumor subtypes (p < 0.001). Although PAX2 mRNA expression levels 
did not differ between ccRCC and pRCC, both were significantly higher when compared to 
chrRCC and oncocytoma (p < 0.001, except for papillary vs. oncocytoma: p = 0.011). 
Moreover, mRNA expression levels in oncocytomas also differed significantly from those 
of chrRCC (p < 0.001). 
 
Table 9: Distribution of PAX2 mRNA expression levels [(PAX2/HPRT1) × 1000 expressed as 
median (interquartile range)] according to renal cell tumor subtype. 
RCT Subtype 
mRNA expression 
Median (interquartile range) 
Clear cell 9598.6 (3717.0 – 16581.9) 
Papillary 7464.8 (1390.2 – 18196.0) 
Chromophobe 424.5 (135.2 – 974.8) 
Oncocytoma 1942.7 (683.7 – 3815.5) 
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When PAX2 mRNA expression levels were compared with PAX2 immunoexpression 
scoring, negative cases (≤10% immunostained nuclei) showed lower median mRNA levels 
than positive cases (>10% immunostained nuclei), and this difference was statistically 
significant (p = 0.011), as illustrated in Figure 14. When the 50% cutoff value was used the 
same trend was observed and the difference was once again statistically significant (p = 
0.007). 
 
 
 
Figure 14: Boxplot of the distribution of PAX2 mRNA expression levels (Log 10 transformed) 
according to PAX2 immunoexpression scoring using the 10% cutoff value (n=120). 
 
 
No correlation was found between PAX2 mRNA expression levels and patients’ age 
(r= -0.112, p= 0.295) (Figure 15) or pathological tumor stage (p = 0.542) (Figure 16). 
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Figure 15: Scatterplot for the correlation between age and PAX2 expression levels (n=120). 
 
 
 
 
Figure 16: Boxplot of the PAX2 mRNA expression levels (Log10 transformed) distribution according 
to the pathological stage (n = 90). 
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However, PAX2 mRNA expression levels differed significantly among the Fuhrman 
grades (p < 0.001) (Figure 17). Grade 4 tumors displayed the lowest relative median levels 
and these statistically differed from those of grade 2 and grade 3 tumors (p < 0.01 for 
both).  
 
 
Figure 17: Boxplot of the PAX2 mRNA expression levels (Log10 transformed) distribution according 
to the Fuhrman grading (n = 90). 
 
 
 
3. PAX2 promoter methylation assessment 
 
The promoter methylation status was first assessed using primers specific for the 
promoter region spanning -676 to -846, in relation to the transcriptional start point, 
according to Wu et al. (Wu et al., 2005). Methylation of CpG dinucleotides located in this 
region was not detected in any of the tumor (Figure 18) or normal (Figure 19) tissue 
samples. 
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Figure 18: Representative methylation-specific PCR results from the analysis of PAX2 promoter 
region (-676 to -846; primer set 1) in renal cell tumors. A visible PCR product in lanes U indicates the 
presence of unmethylated alleles whereas a PCR product in lanes M indicates the presence of methylated 
alleles. C+: fully methylated DNA, positive control for methylated samples; C-: fully unmethylated DNA, 
positive control for unmethylated samples; H2O: negative control. U: lane for unmethylated MSP; M: lane 
for methylated MSP. 
 
 
Figure 19: Representative methylation-specific PCR results from the analysis of PAX2 promoter 
region (-676 to -846; primer set 1) in normal kidney tissues. A visible PCR product in lanes U indicates the 
presence of unmethylated alleles whereas a PCR product in lanes M indicates the presence of methylated 
alleles. C+: fully methylated DNA, positive control for methylated samples; C-: fully unmethylated DNA, 
positive control for unmethylated samples; H2O: negative control. U: lane for unmethylated MSP; M: lane 
for methylated MSP. 
 
These primers were also tested in DNA from normal endometrium as Wu and 
colleagues reported the presence of PAX2 promoter methylation in this tissue using these 
same primer sequences (Wu et al., 2005). As shown in Figure 20, all normal endometrium 
tissue samples tested were found to be unmethylated for PAX2. 
 
Figure 20: Representative methylation-specific PCR results from the analysis of PAX2 promoter 
region (-676 to -846; primer set 1) in normal endometrium tissues. A visible PCR product in lanes U 
indicates the presence of unmethylated alleles whereas a PCR product in lanes M indicates the presence of 
methylated alleles. C+: fully methylated DNA, positive control for methylated samples; C-: fully 
unmethylated DNA, positive control for unmethylated samples; H2O: negative control. U: lane for 
unmethylated MSP; M: lane for methylated MSP. 
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Because Metsuyanim et al., 2008 reported PAX2 methylation in a region downstream 
(-489 to -628 in relation to the transcriptional start site) of that analyzed by Wu et al., we 
also used the set of primers published by the former researchers (Metsuyanim et al., 2008) 
in our set of samples. However, no methylation was found neither in renal tumors (Figure 
21) nor in normal renal tissues (Figure 22). 
 
 
 
Figure 21: Representative methylation-specific PCR results from the analysis of PAX2 promoter 
region (-489 to -628; primer set 2) in renal cell tumors. A visible PCR product in lanes U indicates the 
presence of unmethylated alleles whereas a PCR product in lanes M indicates the presence of methylated 
alleles. C+: fully methylated DNA, positive control for methylated samples; C-: fully unmethylated DNA, 
positive control for unmethylated samples; H2O: negative control. U: lane for unmethylated MSP; M: lane 
for methylated MSP. 
 
 
 
Figure 22: Representative methylation-specific PCR results from the analysis of PAX2 promoter 
region (-489 to -628; primer set 2) in normal kidney tissues. A visible PCR product in lanes U indicates the 
presence of unmethylated alleles whereas a PCR product in lanes M indicates the presence of methylated 
alleles. C+: fully methylated DNA, positive control for methylated samples; C-: fully unmethylated DNA, 
positive control for unmethylated samples; H2O: negative control. U: lane for unmethylated MSP; M: lane 
for methylated MSP. 
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4. FISH findings 
 
All 30 chrRCC cases were tested for chromosome 10/PAX2 copy number using a 
centromeric FISH probe targeting chromosome 10 and a probe targeting the PAX2 gene, 
respectively. Four of these chrRCC samples were not technically analyzable (NA). From 
the remainder cases, chromosome 10 loss was seen in 18 (69%) tumors, whereas gain was 
seen in 2 (8%) chrRCC cases. No ch10/PAX2 copy number change was observed in the 
remaining chrRCC cases. PAX2 locus deletion alone was not found in any of the 
analyzed samples. Figure 23 shows representative FISH images from the analyzed 
chrRCC. 
 
 
Figure 23: Representative FISH images from chromophobe RCC (chromosome 10 probe in red; 
PAX2 probe in green). (A) Two copies of chromosome 10 centromere and two copies of PAX2 (normal). (B) 
One copy of chromosome 10 centromere and one copy of PAX2 (monosomy). (C) Three copies of 
chromosome 10 centromere and three copies of PAX2 (trisomy). (D) Four copies of chromosome 10 
centromere and four copies of PAX2 (tetrasomy). 
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Table 10: FISH results for ch10/PAX2 copy number and distribution of the immunoexpression 
frequencies and mRNA expression levels, in chrRCC cases. 
FISH analysis 
Immunoexpression, n (%) mRNA expression 
Median 
(interquartile range) 
10% cutoff 50% cutoff 
- + - +  
Monosomy 17 (94) 1 (6) 18 (100) 0 (0) 213.2 (104.9 – 1000.4) 
No ch10 loss 1 (17) 5 (83) 4 (67) 2 (33) 524.7 (114.1 – 1508.3) 
Polysomy  0 (0) 2 (100) 1 (50) 1 (50) 384.7 and 527.7 * 
* Descriptive values 
 
Significant differences in PAX2 immunoexpression were observed among the three 
categories of ch10/PAX2 copy number changes, when both the 10% (p < 0.001) and the 
50% (p = 0.018) cutoff values were used (Table 10). Moreover, Somers’d directional 
measure revealed a strong positive association between the immunoexpression frequency 
and the ch10/PAX2 copy number changes, for both 10% (d = 0.8, p < 0.001) and 50% (d = 
0.498, p = 0.041) immunoexpression cutoff values.  
Although no statistical association was found between PAX2 mRNA expression and 
ch10/PAX2 copy number (p = 0.919), a positive trend was observed between these two 
parameters (Figure 24). 
 
Figure 24: Boxplot of the PAX2 mRNA expression levels (Log10 transformed) distribution according 
to the FISH results (n = 26). 
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DISCUSSION 
 
PAX2 is an important transcription factor intensely expressed during kidney 
development (Chi and Epstein, 2002), which is downregulated in the latter phases of 
differentiation in most of the kidney structures (Dressler and Woolf, 1999). In the mature 
kidney, PAX2 expression is restricted to a few structures, namely the collecting ducts and 
the distal tubules, where is responsible for promoting osmotic tolerance and protecting 
cells from apoptosis due to high sodium chloride and urea exposure (Cai et al., 2005). The 
mechanism by which PAX2 silencing occurs at the end of the kidney development is still 
controversial as some authors reported that PAX2 promoter methylation was responsible 
for this downregulation (Metsuyanim et al., 2008), whereas others suggested WT1 
mediated repression (Ryan et al., 1995). Moreover, PAX2 has been reported to function as 
an oncogene, conferring proliferative and apoptosis inhibitory characteristics to cells in 
several tumor models (Robson et al., 2006), including renal cell tumors (Gnarra and 
Dressler, 1995). Finally, diffuse protein expression of PAX2 has been reported to be 
frequent in three of the most prevalent RCT subtypes - ccRCC, pRCC and oncocytoma - 
but not in chrRCC, suggesting its use for differential diagnosis in difficult cases (Mazal et 
al., 2005; Memeo et al., 2007; Gupta et al., 2009). 
In this study, immunohistochemical analysis of PAX2 expression disclosed 
significant differences among the four major subtypes of RCT. ccRCC and oncocytoma 
showed the highest frequency of positive cases (immunoexpression > 10% of tumor cells), 
whereas chrRCC showed the opposite trend. These results are in general agreement with 
previously published reports (Mazal et al., 2005; Memeo et al., 2007; Gupta et al., 2009), 
although some differences were apparent mainly in the frequency of positive cases among 
chrRCC (33.3%). Because the same cutoff value was used, it is likely that methodological 
differences underlie these discrepant results. Indeed, we used a monoclonal antibody 
(which tends to be more specific), in a 1/3000 dilution, whereas all the aforementioned 
studies used polyclonal antibodies in 1/50 and 1/100 dilutions (Mazal et al., 2005; Memeo 
et al., 2007; Gupta et al., 2009). Thus, the higher frequency of PAX2 immunoreactivity in 
chrRCC found in our study is not due neither to lack of antibody specificity nor to 
excessive concentration. 
Since chrRCC (a malignant tumor) and oncocytoma (a benign tumor) may be 
difficult to discriminate morphologically, although they are distinct entities with different 
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prognosis and clinical behavior, we also aimed to confirm the potential of PAX2 as a 
differential biomarker in the distinction between these two tumor subtypes. We thus 
determined the validity estimates using the 10% or the 50% and compared with previously 
published data (Mazal et al., 2005; Memeo et al., 2007; Gupta et al., 2009). Our results 
follow the same trend of those studies, i.e., the 10% cutoff value offers the highest 
specificity, whereas, as expected, the 50% cutoff value displays the highest sensitivity. The 
more discrepant values are those of Mazal and co-workers as they only reported PAX2 
positivity in 14% of oncocytomas, against 87 to 100% of positivity in our study and those 
of Memeo et al. and Gupta et al. (Mazal et al., 2005; Memeo et al., 2007; Gupta et al., 
2009). Moreover, the validity estimates obtained using a polyclonal antibody (Mazal et al., 
2005; Memeo et al., 2007; Gupta et al., 2009) are superior to those of our study, in which a 
monoclonal antibody was used, suggesting the use of a polyclonal antibody for the purpose 
of ancillary tool for histopathological diagnosis. 
Interestingly, no significant differences in PAX2 immunoreactivity were found 
between type 1 and type 2 pRCC, corroborating the findings of Mazal et al. (Mazal et al., 
2005), notwithstanding the methodological differences. Although pRCC types 1 and 2 
have been increasingly recognized as distinct subtypes, they are indistinguishable 
concerning PAX2 protein expression. 
In line with the observations of PAX2 protein expression, PAX2 mRNA expression 
also disclosed significant differences among the four RCT subtypes. However, the highest 
levels were observed in pRCC and ccRCC, whereas oncocytomas showed intermediate 
levels, and chrRCCs displayed the lowest levels of PAX2 mRNA. Importantly, associations 
between PAX2 mRNA levels and protein immunoexpression were also apparent, using 
both immunohistochemical cutoff values, implying that PAX2 transcription and translation 
are correlated, although this might not be linear. The differences in PAX2 expression 
between pRCC and ccRCC on the one hand, and chrRCC and oncocytoma, on the other, 
may be related with the site of origin of each tumor type and may, thus, reflect distinct 
carcinogenic pathways. Indeed, whereas the former derive from proximal tubule cells, the 
latter originate from cortical collecting duct cells (Bodmer et al., 2002). This is a 
somewhat unexpected finding because in normal renal tissue PAX2 expression is restricted 
to the distal portion of the nephron. Taken together, these findings suggest that PAX2 is 
overexpressed in pRCC and ccRCC, whereas in chrRCC it is underexpressed, when 
compared to their normal cell counterparts. Hypothetically, oncocytomas retain the normal 
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PAX2 expression patterns. This model is in accordance with the putative proto-oncogenic 
function of the PAX2 gene (Robson et al., 2006), as pRCC and ccRCC are malignant 
neoplasms and oncocytoma is a benign tumor. Therefore, the loss of PAX2 expression in 
chrRCC might be interpreted as a bystander alteration and it is tempting to speculate 
whether this might contribute the less aggressive clinical behavior of chrRCC compared to 
pRCC and ccRCC. 
Correlation analyses revealed similar trends in PAX2 expression at the protein or 
transcript levels and tumor grade, disclosing significant inverse correlations. Although 
these findings were somewhat unpredicted owing to the role ascribed to PAX2 as a 
transcription factor, our results are in agreement with those of Mazal et al., who also 
reported a decrease or lack of PAX2 immunoexpression with increasing Fuhrman grade 
(Mazal et al., 2005), and of Luu et al., although a different grading system was used and 
only ccRCC were analyzed (Luu et al., 2009). Concerning pathological tumor stage, 
however, only PAX2 immunoexpression showed a significant inverse correlation, whereas 
the same trend was not apparent at the mRNA level. The reason for this discrepancy is not 
immediately apparent and may derive from the higher heterogeneity of the staging system 
compared to the more homogeneous nuclear grading system. 
Another main objective of this study was to investigate the mechanism underlying 
the differential expression of PAX2 among RCT subtypes. Two possibilities for PAX2 gene 
downregulation were hypothesized: PAX2 promoter methylation and/or deletion. The 
former possibility was based on the existence of a CpG island in the promoter region and 
the putative role of promoter methylation in PAX2 gene silencing at the final stages of 
kidney development (Metsuyanim et al., 2008). The latter hypothesis stemmed from the 
observation that loss of chromosome 10 (to which PAX2 is mapped) is a frequent event in 
chrRCC (Mazal et al., 2005; Memeo et al., 2007; Gupta et al., 2009). 
To test the PAX2 promoter methylation hypothesis, methylation-specific PCR was 
performed not only in chrRCC but also in the remainder RCT subtypes and normal kidney 
tissue samples, using two different sets of primers that anneal to two adjacent regions in 
the promoter (Wu et al., 2005; Metsuyanim et al., 2008). These regions have been 
previously reported to be involved in PAX2 gene transcription regulation. Strikingly, no 
methylation was detected in those two regions in any of the analyzed RCT samples, 
including chrRCC, nor in normal kidney tissues. Furthermore, no methylation was found, 
either, in normal endometrium (five random samples), which was previously reported to 
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harbor PAX2 promoter methylation using one of the primers sets (Wu et al., 2005; 
Metsuyanim et al., 2008). In addition, we tested for methylation using the other set of 
primers and the result was negative. Importantly, we demonstrated PAX2 protein 
expression in endometrial glands [which were negative according to Wu and co-workers 
(Wu et al., 2005; Metsuyanim et al., 2008)], thus validating the aforementioned 
methylation analysis of the PAX2 promoter. Moreover, our results are in accordance with 
those of Luu et al. which also did not find PAX2 promoter methylation in ccRCC or in 
normal kidney tissues (Luu et al., 2009).  
To investigate the chromosome 10 loss hypothesis, FISH analysis using specific 
probes for chromosome 10 and for the PAX2 gene was performed in all cases of chrRCC 
included in this study. As expected, the vast majority of chrRCC cases displayed 
chromosome 10 monosomy, which is in accordance with the results reported by Brunelli 
and colleagues (Brunelli et al., 2005), and no case of specific PAX2 locus deletion was 
observed. These findings might explain the lower PAX2 mRNA levels and protein 
expression globally observed in this tumor subtype. Remarkably, a significant association 
with the immunoexpression findings was apparent, indicating that chromosome 10 loss is 
the most likely mechanism underlying PAX2 loss of expression. This hypothesis is further 
supported by the fact that cases with no copy number change or with polysomy showed 
higher frequency of PAX2 immunoexpression. Indeed, this trend was confirmed by the 
Somers’d test. Interestingly, the highest correlation value was found for the 10% 
immunoexpression cutoff, probably because a similar cutoff was applied to FISH analysis. 
Unexpectedly, no statistically significant differences were found for PAX2 mRNA levels  
according to ch10/PAX2 copy number findings, although a slight trend for increased 
mRNA levels in cases without ch10 monosomy was suggested. Because we previously 
found a significant association between PAX2 protein expression and transcript levels, this 
result is probably due to the limited number of cases analyzed. 
This is the first study reporting FISH findings for PAX2 gene in RCTs, to the best of 
our knowledge. In fact, PAX2 locus specific deletion was not observed in any of the 
analyzed chrRCC samples. Therefore, we may conclude that this is not the mechanism 
underlying the lower PAX2 mRNA and protein expression in the cases not showing 
chromosome 10 monosomy. Therefore, other yet unknown genetic or epigenetic 
mechanisms might justify the expression results in this small subset cases. Moreover, it is 
tempting to speculate whether PAX2 gene amplification might be responsible for PAX2 
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overexpression in ccRCC, pRCC and oncocytomas since no ch10 copy number changes 
have been reported in these RCT subtypes. 
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Although PAX2 immunoexpression results diverge slightly between our study and 
those previously reported, our findings confirm that it still might be useful as an important 
ancillary tool in the distinction between the two morphologically similar entities, chrRCC 
and renal oncocytoma. 
Our study was the first to determine the PAX2 mRNA expression levels for the four 
most representative RCT subtypes, and to associate them with the respective protein 
expression levels. PAX2 expression was variable among the different histological 
subtypes, and the lowest expression, both for mRNA levels and protein, was found in the 
chrRCC subtype.  
Importantly, our results also indicate that PAX2 promoter methylation is not 
implicated in gene silencing in chrRCC or in normal kidney. Instead, the frequent 
chromosome 10 loss observed in chrRCC samples, and the significant correlation with 
PAX2 immunoexpression categories, indicate that this genetic alteration is the major cause 
for PAX2 underexpression in this tumor subtype. Nonetheless, additional studies are 
required to accurately determine additional genetic/epigenetic regulation mechanisms 
underlying PAX2 differential expression in other renal cell tumors. 
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ONGOING ASSAYS  
 
This study will be completed with subsequent analysis which will further elucidate 
the mechanism underlying PAX2 gene differential expression in these four major RCT 
subtypes. 
Presently, we are performing FISH analysis on the remaining RCT subtypes used in 
this study. This analysis might determine whether PAX2 amplification is the genetic 
mechanism responsible for its overexpression in ccRCC and pRCC. 
Furthermore, we aim at sequencing (bisulfite sequencing) the entire CpG island of 
the PAX2 promoter region to assess if PAX2 promoter methylation may occur in other 
regions besides the ones assessed in this study by reference to previously published reports.
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